5-HT Receptor

Serotonin Receptor; 5-hydroxytryptamine Receptor

5-HT receptors (Serotonin receptors) are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. Type: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7. They mediate both excitatory and inhibitory neurotransmission. The serotonin receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand. The serotonin receptors modulate the release of many neurotransmitters, as well as many hormones. The serotonin receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics,antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

(4E)-SUN9221

Cat. No.: HY-U00367

(4E)-SUN9221 is a potent antagonist of **α1-adrenergic receptor** and **5-HT2 receptor**, with antihypertensive and anti-platelet aggregation activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Mirtazapine

((R)-Org3770; (R)-6-Azamianserin)

Cat. No.: HY-B0352B

(R)-Mirtazapine ((R)-Org3770) is a R(−)-enantiomer of Mirtazapine with antinociceptive properties in an animal model of acute thermal nociception. (R)-Mirtazapine is a **5-HT$_3$ receptor** antagonist. (R)-Mirtazapine is mainly metabolized by CYP3A4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Mirtazapine D3

((R)-Org3770 D3; (R)-6-Azamianserin D3)

Cat. No.: HY-B0352BS

(R)-Mirtazapine D3 ((R)-Org3770 D3) is a deuterium labeled (R)-Mirtazapine. (R)-Mirtazapine is a R(−)-enantiomer of Mirtazapine with antinociceptive properties in an animal model of acute thermal nociception. (R)-Mirtazapine is a **5-HT$_3$ receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Praziquantel-d11

Cat. No.: HY-126057S

(R)-Praziquantel D11 is the deuterium labeled (R)-Praziquantel. (R)-Praziquantel, the active enantiomer of Praziquantel, is a partial agonist of the human 5-HT2B receptor. (R)-Praziquantel acts as an antischistosomal eutomer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R,R)-Palonosetron Hydrochloride

Cat. No.: HY-A0021C

(R,R)-Palonosetron Hydrochloride is the active enantiomer of Palonosetron.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Rotigotine hydrochloride

Cat. No.: HY-15394

(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(Rac)-Rotigotine-d7 hydrochloride

Cat. No.: HY-15394S

(Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-SEP-363856

((Rac)-SEP-856)

Cat. No.: HY-136109B

(Rac)-SEP-363856 is the racemate of SEP-363856. SEP-363856SEP-856, an orally active and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-WAY-161503

Cat. No.: HY-103138A

(Rac)-WAY-161503 is a potent, selective, highly affinity **5-HT$_{2C}$ receptor** agonist with a K_i of 4 nM and an EC_{50} of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT$_{2C}$ than 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(S)-Amisulpride

(Esamisulpride; SEP-4199)

Cat. No.: HY-126068

(S)-Amisulpride (Esamisulpride) is a potent **dopamine D$_2$/D$_3$ receptor** antagonist. (S)-Amisulpride is an antagonist at the **5-HT$_7$ receptor** with a K_i of 900 nM. (S)-Amisulpride has antipsychotic and antidepressant effects.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(S)-Mirtazapine

((S)-Org3770; (S)-6-Azamianserin) Cat. No.: HY-B0352A

(S)-Mirtazapine ((S)-Org3770) is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception. (S)-Mirtazapine is a stereoselective **5-HT$_2$ receptor** antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Mirtazapine D3

((S)-Org3770 D3; (S)-6-Azamianserin D3) Cat. No.: HY-B0352AS

(S)-Mirtazapine D3 ((S)-Org3770 D3) is a deuterium labeled (S)-Mirtazapine. (S)-Mirtazapine is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception.(S)-Mirtazapine is a stereoselective **5-HT$_2$ receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-Thiothixene

Cat. No.: HY-108324

(Z)-Thiothixene is an antagonist of **serotonergic receptor** extracted from patent US 20150141345 A1.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

(±)-Fabesetron hydrochloride

((±)-FK1052) Cat. No.: HY-101638

(±)-Fabesetron hydrochloride ((±)-FK1052) is the racemate of Fabesetron hydrochloride, which is a potent **5-HT3** and **5-HT4** receptor dual antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2'-O-Methylisoliquiritigenin

Cat. No.: HY-N1745

2'-O-Methylisoliquiritigenin, isolated from the Arachis species, up-regulates **5-HT, NE, DA** and **GABA** pathways, but does not put a very significant effect on ne NE pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Methyl-5-HT (2-Methyl-5-hydroxytryptamine; 2-Methylserotonin; 2-Me-5-HT)

Cat. No.: HY-19358

2-Methyl-5-HT (2-Methyl-5-hydroxytryptamine) is a potent and selective **5-HT$_3$ receptor** agonist. 2-Methyl-5-HT is shown to display anti-depressive-like effects.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

2-Methyl-5-HT hydrochloride (2-Methyl-5-hydroxytryptamine hydrochloride; 2-Methylserotonin hydrochloride; ...)

Cat. No.: HY-19358A

2-Methyl-5-HT hydrochloride (2-Methyl-5-hydroxytryptamine hydrochloride) is a potent and selective **5-HT$_3$ receptor** agonist. 2-Methyl-5-HT hydrochloride is shown to display anti-depressive-like effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Methyl-5-HT maleate (2-Methyl-5-hydroxytryptamine maleate; 2-Methylserotonin maleate; 2-Me-HT maleate)

Cat. No.: HY-19358B

2-Methyl-5-HT maleate (2-Methyl-5-hydroxytryptamine maleate) is a potent and selective **5-HT$_3$ receptor** agonist. 2-Methyl-5-HT maleate is shown to display anti-depressive-like effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Hydroxy agomelatine

Cat. No.: HY-133111

3-Hydroxy agomelatine is a metabolite of Agomelatine. 3-Hydroxy agomelatine is a **5-HT$_{2C}$ receptor** antagonist with an **IC$_{50}$** of 3.2 μM and a **K$_i$** of 1.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

3-Hydroxy agomelatine D3

Cat. No.: HY-133111S

3-Hydroxy agomelatine D3 is a deuterium labeled 3-Hydroxy agomelatine. 3-Hydroxy agomelatine is a **5-HT$_{2C}$ receptor** antagonist with an **IC$_{50}$** of 3.2 μM and a **K$_i$** of 1.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Hydroxy agomelatine-d3-1

Cat. No.: HY-133111S1

3-Hydroxy agomelatine-d3-1 is the deuterium labeled 3-Hydroxy agomelatine. 3-Hydroxy agomelatine is a metabolite of Agomelatine. 3-Hydroxy agomelatine is a **5-HT$_{2C}$ receptor** antagonist with an **IC$_{50}$** of 3.2 μM and a **K$_i$** of 1.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4,4-Diphenylbutylamine hydrochloride

Cat. No.: HY-141422A

4,4-Diphenylbutylamine shows affinity for the **5-HT$_{2A}$** and **H$_1$** receptors with K$_i$s of 2589 and 1670 nM, respectively.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 50 mg

4-Hydroxy trimethoprim-d9

Cat. No.: HY-B0071S

4-Hydroxy trimethoprim-d9 is the deuterium labeled Granisetron. Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

4F 4PP oxalate

Cat. No.: HY-100970

4F 4PP (oxalate) is a selective **5-HT2A** antagonist with almost as high affinity (**K$_i$**= 5.3 nM) as ketanserin but with a much lower affinity for 5-HT2C sites (**K$_i$**= 620 nM).



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

5-HT1A modulator 1

Cat. No.: HY-100290

5-HT1A modulator 1 displays very high affinities for the **5HT$_{1A}$**, **adrenergic α$_1$** and **dopamine D$_2$ receptor** with **IC$_{50}$**s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.



Purity: 97.12%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT1A modulator 2 hydrochloride

Cat. No.: HY-136621

5-HT1A modulator 2 hydrochloride, a derivative of 8-OH-DPAT (HY-112061), is a modulator of **5-HT$_{1A}$** with a **K$_i$** of 53 nM for 5-HT$_{1A}$ binding.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

5-HT2 antagonist 1

Cat. No.: HY-U00365

5-HT2 antagonist 1 is a potent antagonist of **5-HT2 receptor**, with weak **α1 adrenoceptor** blocking activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT2A antagonist 1

Cat. No.: HY-U00286

5-HT2A antagonist 1 is a **5-HT2A** antagonist extracted from patent US5728835A and JP 1007727. 5-HT2A antagonist 1 may be useful in treatment of gastrointestinal disorders circulatory disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT2A receptor agonist-1

Cat. No.: HY-145393

5-HT2A receptor agonist-1 is a **5-HT2A** receptor agonist with the **EC$_{50}$** of 5.54 nM. 5-HT2A receptor agonist-1 can be used for the research of mood disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT3 antagonist 1

Cat. No.: HY-U00368

5-HT3 antagonist 1 is a potent and selective antagonist of **serotonin 3 (5-HT3) receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT3 antagonist 2

Cat. No.: HY-U00408

5-HT3 antagonist 2 is a **5-HT3** receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT3 antagonist 3

Cat. No.: HY-U00322

5-HT3 antagonist 3 (Compound 15b) is a high-affinity **5-HT3 receptor** antagonist. 5-HT3 antagonist 3 binds to 5-HT3 receptors in rat brain cortical membranes with K_i of 0.25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT3-In-1

Cat. No.: HY-U00413

5-HT3-In-1 is extracted from patent EP0748807A1, compound example 8. It shows **5-HT3** inhibition activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT4 antagonist 1

Cat. No.: HY-100170

5-HT4 antagonist 1 is a **5-HT$_4$ receptor** antagonist with a **pK$_i$** of 9.6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT6/5-HT2AR antagonist-1

Cat. No.: HY-145862

5-HT6/5-HT2AR antagonist-1 is a potent dual **5-HT$_6$/5-HT$_{2A}$R** antagonist with K_i values of 11 nM and 39 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT6/7 antagonist 1

Cat. No.: HY-101622

5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes **5-HT6/7/2A** and **D2** receptors, without interacting with M1 receptors and hERG channels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT7 agonist 1

Cat. No.: HY-109527

5-HT7 agonist 1 is a selective **5-HT7 receptor** agonist, with an **IC$_{50}$** of 222.93 nM, can be used for the 5-HT7 receptor related disease, such as CNS disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5HT6-ligand-1

Cat. No.: HY-U00126

5HT6-ligand-1 is a potent **5-HT6** receptor ligand with a K_i of 1.43 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Desmethyl-3-hydroxyagomelatine

(3-Hydroxy-7-desmethyl agomelatine)

Cat. No.: HY-133112

7-Desmethyl-3-hydroxyagomelatine (3-Hydroxy-7-desmethyl agomelatine), a metabolite of Agomelatine, has less activity than Agomelatine. Agomelatine is a **melatonergic** (**MT1** and **MT2**) agonist and **serotonergic** (**5HT2C**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Desmethyl-3-hydroxyagomelatine-d3

(3-Hydroxy-7-desmethyl agomelatine-d3)

Cat. No.: HY-133112S

7-Desmethyl-3-hydroxyagomelatine-d3 (3-Hydroxy-7-desmethyl agomelatine-d3) is the deuterium labeled 7-Desmethyl-3-hydroxyagomelatine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Desmethyl-agomelatine

Cat. No.: HY-133113

7-Desmethyl-agomelatine is a metabolite of Agomelatine. Agomelatineis a potent agonist at melatonin receptors (MT1 and MT2), and also is an antagonist of 5-HT2C.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Hydroxy-DPAT hydrobromide

(8-OH-DPAT hydrobromide)

Cat. No.: HY-15688

8-Hydroxy-DPAT hydrobromide (8-OH-DPAT hydrobromide) is a potent and selective **5-HT$_{1A}$** agonist with a **pIC$_{50}$** of 8.19. 8-Hydroxy-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT$_1$ binding site.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-OH-DPAT

(8-Hydroxy-DPAT)

Cat. No.: HY-112061

8-OH-DPAT is a potent and selective **5-HT** agonist, with a **pIC$_{50}$** of 8.19 for 5-HT1A and a **K$_i$** of 466 nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC$_{50}$, 5.42), 5-HT (pIC$_{50}$ <5).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

8-OH-DPAT-d7 hydrobromide

(8-Hydroxy-DPAT-d7 hydrobromide)

Cat. No.: HY-112061S

8-OH-DPAT-d7 hydrobromide (8-Hydroxy-DPAT-d7 hydrobromide) is the deuterium labeled 8-OH-DPAT hydrobromide. 8-OH-DPAT is a potent and selective **5-HT** agonist, with a **pIC$_{50}$** of 8.19 for 5-HT1A and a **K$_i$** of 466 nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC$_{50}$, 5.42), 5-HT (pIC$_{50}$ <5).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

A-582941 dihydrochloride

Cat. No.: HY-59201A

A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of **α7 nAChR**, with **K$_i$**s of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human **5-HT$_3$ receptor** with a **K$_i$** of 150 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abaperidone

Cat. No.: HY-101619

Abaperidone is a potent antagonist of **5-HT$_{2A}$receptor** and **dopamine D$_2$ receptor** with **IC$_{50}$**s of 6.2 and 17 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AChE-IN-5

Cat. No.: HY-144272

AChE-IN-5 (compound 5) exhibits strong in vitro bioactivity against **AChE/5-HT$_{1A}$/SERT** and exhibits good BBB permeability. AChE-IN-5 shows IC$_{50}$ value 2.29 nM against AChE, EC$_{50}$ 58.6 nM against 5-HT$_{1A}$ and IC50 value against SERT. Orally active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adoprazine

(SLV313)

Cat. No.: HY-14782

Adoprazine (SLV313) is a full **5-HT$_{1A}$ receptor** agonist with a **pEC$_{50}$** of 9 at cloned h5-HT$_{1A}$ receptors. Adoprazine (SLV313) is a full **D$_2$** and **D$_3$ receptor** antagonist with **pA$_2$s** of 9.3 and 8.9 at hD$_2$ and hD$_3$ receptors, respectively.



Purity: 98.10%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Agomelatin-d3

(S-20098-d3)

Cat. No.: HY-17038S2

Agomelatin-d3 (S-20098-d3) is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of **MT1** and **MT2** receptors with **K$_i$**s of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Agomelatine

(S-20098)

Cat. No.: HY-17038

Agomelatine (S-20098) is a specific agonist of **MT1** and **MT2** receptors with **K$_i$**s of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.



Purity: 98.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Agomelatine (L(+)-Tartaric acid)

(S-20098 L(+)-Tartaric acid) Cat. No.: HY-17038B

Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of **MT1** and **MT2** receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Agomelatine hydrochloride

(S-20098 hydrochloride) Cat. No.: HY-17038A

Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of **MT1** and **MT2** receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Agomelatine-d4

(S-20098-d4) Cat. No.: HY-17038S1

Agomelatine-d4 (S-20098-d4) is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of **MT1** and **MT2** receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Agomelatine-d6

(S-20098-d6) Cat. No.: HY-17038S

Agomelatine-d6 (S-20098-d6) is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Almotriptan

Cat. No.: HY-B0383A

Almotriptan is a 5-HT1B/1D-receptor agonist used to treat migraine.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Almotriptan malate

(PNU180638) Cat. No.: HY-B0383

Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Almotriptan-d6 hydrochloride

Cat. No.: HY-B0383AS

Almotriptan-d6 hydrochloride is the deuterium labeled Almotriptan. Almotriptan is a 5-HT_{1B}/$_{1D}$-receptor agonist used to treat migraine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Alniditan

(Alnitidan) Cat. No.: HY-101698

Alniditan (Alnitidan) is a potent **5-HT_{1B}** and **5-HT_{1D} receptors** agonist, with **IC_{50}**s of 1.7 nM and 1.3 nM for **h5-HT_{1B}** and **h5-HT_{1D} receptors** in HEK293 cells, respectively. Alniditan has migraine-preventive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alniditan dihydrochloride

(Alnitidan dihydrochloride) Cat. No.: HY-101698B

Alniditan (Alnitidan) dihydrochloride is a potent **5-HT_{1B}** and **5-HT_{1D} receptors** agonist, with **IC_{50}**s of 1.7 nM and 1.3 nM for **h5-HT_{1B}** and **h5-HT_{1D} receptors** in HEK293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Alosetron

(GR 68755; GR 68755X) Cat. No.: HY-70050A

Alosetron (GR 68755) is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Alosetron ((Z)-2-butenedioate) (GR 68755 ((Z)-2-butenedioate); GR 68755X ((Z)-2-butenedioate))

Cat. No.: HY-70050B

Alosetron (GR 68755) (Z)-2-butenedioate is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron (Z)-2-butenedioate is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Alosetron (Hydrochloride(1:X)) (GR 68755 (Hydrochloride(1:X)); GR 68755X (Hydrochloride(1:X)))

Cat. No.: HY-70050

Alosetron (GR 68755) Hydrochloride(1:X) is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron Hydrochloride(1:X) is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Alosetron D3 Hydrochloride (GR-68755C D3)

Cat. No.: HY-70050CS

Alosetron D3 Hydrochloride (GR-68755C D3) is deuterium labeled Alosetron, which is a serotonin 5HT3-receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alosetron Hydrochloride (GR 68755C; GR 68755 Hydrochloride; GR 68755X Hydrochloride)

Cat. No.: HY-70050C

Alosetron Hydrochloride (GR 68755C) is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron Hydrochloride is used for the research of irritable bowel syndrome (IBS).



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Alosetron-13C,d3 (GR 68755-13C,d3; GR 68755X-13C,d3)

Cat. No.: HY-70050AS1

Alosetron-13C,d3 (GR 68755-13C,d3) is the 13C- and deuterium labeled Alosetron. Alosetron (GR 68755) is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alosetron-d3 (GR 68755-d3; GR 68755X-d3)

Cat. No.: HY-70050AS

Alosetron-d3 (GR 68755-d3) is a deuterium labeled Alosetron. Alosetron is a serotonin **5HT3-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alprenolol ((RS)-Alprenolol; dl-Alprenolol)

Cat. No.: HY-B1517

Alprenolol is a non-selective beta blocker as well as 5-HT1A receptor antagonist. The reference for administration is 10 mg/kg.



Purity: 99.87%
Clinical Data: Launched
Size: 50 mg, 100 mg

Alprenolol hydrochloride ((RS)-Alprenolol hydrochloride; dl-Alprenolol hydrochloride)

Cat. No.: HY-B1517A

Alprenolol (hydrochloride) is a non-selective beta blocker as well as 5-HT1A receptor antagonist. The reference for administration is 10 mg/kg.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Alprenolol-d7 hydrochloride ((RS)-Alprenolol-d7 hydrochloride; dl-Alprenolol-d7(hydrochloride))

Cat. No.: HY-B1517AS

Alprenolol-d7 ((RS)-Alprenolol-d7) hydrochloride is the deuterium labeled Alprenolol hydrochloride. Alprenolol hydrochloride is a non-selective beta blocker as well as 5-HT1A receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alverine citrate (NSC 35459)

Cat. No.: HY-B0500

Alverine citrate is a **5-HT$_{1A}$** receptor antagonist, with an **IC$_{50}$** of 101 nM.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

AM9405

Cat. No.: HY-112707

AM9405 is a novel peripherally active **cannabinoid type 1 (CB1)** and **serotonin type 3 receptor** agonist. AM9405 inhibits twitch contraction of the ileum and the colon with **IC_{50}**s of 45.71 and 0.076 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amitriptyline hydrochloride

Cat. No.: HY-B0527A

Amitriptyline hydrochloride is an inhibitor of **serotonin reuptake transporter (SERT)** and **noradrenaline reuptake transporter (NET)**, with **K_i**s of 3.45 nM and 13.3 nM for human SERT and NET, respectively.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amitriptyline-d3 hydrochloride

Cat. No.: HY-135096

Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride).



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Amitriptyline-d6 hydrochloride

Cat. No.: HY-B0527AS

Amitriptyline-d6 hydrochloride is the deuterium labeled Amitriptyline hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 25 mg

Ansofaxine hydrochloride

(LY03005; LPM570065)

Cat. No.: HY-U00096

Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits **serotonin**, **dopamine** and **norepinephrine** reuptake with **IC_{50}** values of 723, 491 and 763 nM, respectively.



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AP521

Cat. No.: HY-100166

AP521 is an agonist of human **5-HT_{1A} receptor** with an **IC_{50}** of 94 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AR-A 2

(AR-A 000002)

Cat. No.: HY-107018

AR-A 2 is a selective **5-HT_{1B} receptor** antagonist, with high affinity to guinea pig cortex **5$HT_{1B/1D}$** and recombinant guinea pig **5-HT_{1B} receptors** (K_i=0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig **5-HT_{1D} receptor** (K_i, 5 nM), and shows an **EC_{50}** of...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aripiprazole

(OPC-14597)

Cat. No.: HY-14546

Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g

Aripiprazole (1,1,2,2,3,3,4,4-d8)

Cat. No.: HY-14546S1

Aripiprazole (1,1,2,2,3,3,4,4-d8) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a K_i of 4.2 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 10 mg

Aripiprazole (D8)

(OPC-14597 D8)

Cat. No.: HY-14546S

Aripiprazole D8 (OPC-14597 D8) is the deuterium labeled Aripiprazole, which is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aripiprazole-d8 N,N-Dioxide

Cat. No.: HY-14546S4

Aripiprazole-d8 N,N-Dioxide is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a K_i of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Aripiprazole-d8 N1-Oxide

Cat. No.: HY-14546S3

Aripiprazole-d8 N1-Oxide is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a K_i of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Aripiprazole-d8 N4-Oxide

Cat. No.: HY-14546S2

Aripiprazole-d8 N4-Oxide is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a K_i of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Arotinolol

Cat. No.: HY-122537A

Arotinolol is a nonselective **α/β-adrenergic receptor** blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand ^{125}I-ICYP to **5HT$_{1B}$**-serotonergic receptor sites.



Purity: 98.23%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AS19

Cat. No.: HY-103142

AS19 is a potent, selective **5-HT$_7$ receptor** agonist with an **IC$_{50}$** value of 0.83 nM and a **K$_i$** of 0.6 nM. AS19 is selective for **5-HT$_7$** over 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{1D}$, and 5-HT$_{5A}$ receptors (**K$_i$**s = 89.7 nM, 490 nM, 6.6 nM and 98.5 nM, respectively).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

Asenapine

(Org 5222)

Cat. No.: HY-10121

Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of **serotonin receptors** (**pK$_i$**: 8.4-10.5), **adrenoceptors** (**pK$_i$**: 8.9-9.5), **dopamine receptors** (**pK$_i$**: 8.9-9.4) and **histamine receptors** (**pK$_i$**: 8.2-9.0).



Purity: 98.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Asenapine hydrochloride

Cat. No.: HY-16567

Asenapine hydrochloride, an antipsychotic, is a **5-HT** (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and **Dopamine** (**D$_2$**, **D$_3$**, **D$_4$**) receptor antagonist with **K$_i$** values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.



Purity: 98.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Asenapine maleate

(Org 5222 maleate)

Cat. No.: HY-11100

Asenapine maleate is a **5-HT** (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and **D2** antagonist with **K$_i$** values of 0.03-4.0 nM, 1.3nM, respectively, and an antipsychotic.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Asenapine-13C,d3 hydrochloride

Cat. No.: HY-16567S

Asenapine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Asenapine-d3

(Org 5222-d3)

Cat. No.: HY-10121S

Asenapine-d3 (Org 5222-d3) is the deuterium labeled Asenapine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Asenapine-d7

(Org 5222-d7)

Cat. No.: HY-10121S1

Asenapine-d7 (Org 5222-d7) is the deuterium labeled Asenapine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Asimilobine

Cat. No.: HY-N7512

Asimilobine is an aporphine isoquinoline alkaloid isolated from plant species of Magnolia obobata Thun. Asimilobine is a **dopamine** biosynthesis inhibitor and a **serotonergic receptor** antagonist. Asimilobine shows an **antimalarial** and anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AVN-492

Cat. No.: HY-101924

AVN-492 is a very specific and highly-selective antagonist with picomolar affinity to **5-HT6R** (K_i=91 pM).



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Azasetron hydrochloride

(Y-25130 hydrochloride)

Cat. No.: HY-B0068

Azasetron (Y-25130) hydrochloride, a benzamide derivative, is a potent and selective **5-HT3** receptor antagonist. Azasetron is used in the study for Chemotherapy-induced nausea and vomiting (CINV).



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Befiradol

(NLX-112; F13640)

Cat. No.: HY-14785

Befiradol (NLX-112) is a selective **5-HT1A** receptor agonist.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Befiradol hydrochloride

(NLX-112 hydrochloride; F 13640 hydrochloride)

Cat. No.: HY-14785A

Befiradol hydrochloride (NLX-112 hydrochloride) is a selective **5-HT$_{1A}$** receptor agonist.



Purity: 99.74%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bemesetron

(MDL 72222)

Cat. No.: HY-B1541

Bemesetron (MDL 72222) is a selective **5-HT$_3$ receptor** antagonist with an **IC$_{50}$** of 0.33 nM. Neuroprotective effect.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg

Benzoctamine hydrochloride

(Ba-30803)

Cat. No.: HY-A0171A

Benzoctamine hydrochloride (Ba-30803) is a psychoactive agent with anti-anxiety effect. Benzoctamine hydrochloride blocks the central postsynaptic serotonin receptors and decreases 5-HT turnover in the brain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benzoctamine-d3 hydrochloride

(Ba-30803-d3)

Cat. No.: HY-A0171AS

Benzoctamine-d3 hydrochloride (Ba-30803-d3) is the deuterium labeled Benzoctamine hydrochloride. Benzoctamine hydrochloride (Ba-30803) is a psychoactive agent with anti-anxiety effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

BGC20-761

Cat. No.: HY-21995

BGC20-761 is a selecvtive **5-HT6** and **dopamine receptor** antagonist (human receptor K_i values: 5-HT6 (20 nM), 5-HT2A (69 nM), D2 (140 nM). BGC20-761, can enhance long-term memory. BGC20-761 has potential utility as an antipsychotic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bifeprunox

Cat. No.: HY-14547

Bifeprunox is a potent **dopamine D2**-like and **5-HT1A receptor** partial agonist with **pK_i**s of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a **pEC_{50}** of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox is an antipsychotic for the research of schizophrenia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIMU 8

Cat. No.: HY-110094

BIMU 8 is a potent and selective **5-HT4** agonist with **EC_{50}**s of 18 nM, 77 nM, and 540 nM for **wild type 5HT4 receptor**, **T3.36A**, and **W6.48A mutant 5-HT4 receptors**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Blonanserin

(AD-5423)

Cat. No.: HY-13575

Blonanserin (AD-5423) is a potent and orally active **5-HT_{2A}** (**K_i**=0.812 nM) and **dopamine D2 receptor** (**K_i** =0.142 nM) antagonist.



Purity: 98.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 100 mg

Blonanserin D8

(AD-5423 D8)

Cat. No.: HY-13575S

Blonanserin D8 (AD-5423 D8) is a deuterium labeled Blonanserin. Blonanserin is a **dopamine D_2/5-HT_2 receptor** antagonist and an atypical antipsychotic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Blonanserin-d5

(AD-5423-d5)

Cat. No.: HY-13575S1

Blonanserin D5 (AD-5423 D5) is a deuterium labeled Blonanserin. Blonanserin is a **dopamine D_2/5-HT_2 receptor** antagonist and an atypical antipsychotic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMY 7378

Cat. No.: HY-100554

BMY 7378 is a selective antagonist of α_{1D}-adrenoceptor (α_{1D}-AR). BMY 7378 binds to membranes expressing the cloned rat α_{1D}-AR with a >100-fold higher affinity (**K_i**=2 nM) than binding to either the cloned rat α_{1A}-AR (**K_i**=800 nM) or the hamster α_{1B}-AR (**K_i**=600 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMY-14802 hydrochloride

(BMY-14802-1; BMS 181100 hydrochloride)

Cat. No.: HY-108509

BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active **sigma receptor** antagonist with an **IC_{50}** of 112 nM. BMY-14802 hydrochloride is also a **5-HT1A** and **adrenergic α1 receptors** agonist. BMY-14802 hydrochloride has antipsychotic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brexpiprazole

(OPC-34712)

Cat. No.: HY-15780

Brexpiprazole (OPC-34712), an atypical antipsychotic drug, is a partial agonist of human **5-HT1A** and **dopamine receptor** with **K_i**s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a **5-HT2A** receptor antagonist with a **K_i** of 0.47 nM.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Brexpiprazole S-oxide

(DM-3411)

Cat. No.: HY-133152

Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Brexpiprazole S-oxide D8

(DM-3411 D8)

Cat. No.: HY-133152S

Brexpiprazole S-oxide D8 (DM-3411 D8) is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brexpiprazole-d8

(OPC-34712-d8)

Cat. No.: HY-15780S

Brexpiprazole D8 (OPC-34712 D8) is a deuterium labeled Brexpiprazole (OPC-34712). Brexpiprazole, an atypical antipsychotic drug, is a partial agonist of human 5-HT1A and dopamine receptor (K_i=0.12 nM and 0.3 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brilaroxazine

(RP5063)

Cat. No.: HY-109112

Brilaroxazine (RP5603) is a potent and orally active multimodal **dopamine (DA)/serotonin (5-HT)** modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRL 54443

Cat. No.: HY-13221

BRL 54443 is a potent **5-HT$_{1E/1F}$** receptor agonist (**K_i** values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BRL-15572 dihydrochloride

Cat. No.: HY-13200

BRL-15572 dihydrochloride is a selective antagonist of **h5-HT1D**, displays high affinity for **h5-HT1D receptors**. BRL-15572 dihydrochloride could be useful pharmacological agents to characterise **5-HT1D receptor** mediated responses.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BRL-15572 hydrochloride

Cat. No.: HY-13200A

BRL-15572 hydrochloride is a selective antagonist of **h5-HT1D**, displays high affinity for **h5-HT1D receptors**. BRL-15572 hydrochloride could be useful pharmacological agents to characterise **5-HT1D receptor** mediated responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromperidol

(R-11333)

Cat. No.: HY-B0901

Bromperidol is a butyrophenone derivative, is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Bromperidol-d4

Cat. No.: HY-B0901S

Bromperidol-d4 is the deuterium labeled Bromperidol. Bromperidol is a butyrophenone derivative, is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Bromperidol-d4-1

(R-11333-d4-1)

Cat. No.: HY-B0901S1

Bromperidol-d4-1 is deuterium labeled Bromperidol.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Buspirone hydrochloride

Cat. No.: HY-B1115

Buspirone hydrochloride is an anxiolytic psychotropic drug, is used to treat generalized anxiety disorder (GAD).



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Buspirone-d8 hydrochloride

Cat. No.: HY-B1115S

Buspirone-d8 hydrochloride is the deuterium labeled Buspirone hydrochloride. Buspirone hydrochloride is an anxiolytic psychotropic drug, is used to treat generalized anxiety disorder (GAD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BW-723C86

Cat. No.: HY-101369

BW-723C86 is a potent and a selective **5-HT2B receptor** agonist. BW-723C86 exhibits anxiolytic-like actions. BW-723C86 also causes hyperphagia and reduced grooming in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cariprazine

(RGH-188)

Cat. No.: HY-14763

Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the **5-HT**$_{1A}$ receptor (K_i=2.6 nM).



Purity: 99.35%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Cariprazine D8

(RGH-188 D8)

Cat. No.: HY-14763S1

Cariprazine D8 (RGH-188 D8) is a deuterium labeled Cariprazine. Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the **5-HT**$_{1A}$ receptor (K_i=2.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cariprazine hydrochloride

(RGH188 hydrochloride)

Cat. No.: HY-14763A

Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the **5-HT**$_{1A}$ receptor (K_i=2.6 nM).



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Cariprazine-d6

(RGH-188-d6)

Cat. No.: HY-14763S

Cariprazine D6 (RGH-188 D6) is a deuterium labeled Cariprazine. Cariprazine Cariprazine is an antipsychotic agent that exhibits high affinity for the D_3 (K_i of 0.085 nM) and D_2 (K_i of 0.49 nM) receptors, and moderate affinity for the **5-HT**$_{1A}$ receptor (K_i of 2.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Cariprazine-d6 hydrochloride

(RGH188-d6 hydrochloride)

Cat. No.: HY-14763S2

Cariprazine-d6 (RGH188-d6) hydrochloride is the deuterium labeled Cariprazine hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CART(62-76)(human,rat)

Cat. No.: HY-P1303

CART(62-76)(human,rat) is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects.

YGQVPMCDAGEQCAV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CART(62-76)(human,rat) TFA

Cat. No.: HY-P1303A

CART(62-76)(human,rat) TFA is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects.

YGQVPMCDAGEQCAV (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cassiaside B2

Cat. No.: HY-N8200

Cassiaside B2 is a protein tyrosine phosphatase 1B **(PTP1B)** and **human monoamine oxidase A (hMAO-A)** inhibitor. Cassiaside B2 possesses antiallergic and is a **5-HT2C** receptor agonist..



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cerlapirdine

(SAM-531; PF-05212365)

Cat. No.: HY-14431

Cerlapirdine (SAM-531, PF-05212365) is a selective and potent full antagonist of the 5-hydroxytryptamine 6 (**5-HT6**) receptor. Cerlapirdine has the potential for researching the Alzheimer's disease.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CGS 12066 dimaleate

Cat. No.: HY-101049

CGS 12066 (dimaleate) dimaleate is a selective **5-HT$_{1B}$ receptor** agonist with an **IC$_{50}$** of 51 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cinanserin hydrochloride

(SQ 10643)

Cat. No.: HY-100943

Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity **5-HT$_2$ receptor** antagonist with a **K$_i$** of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the **5-HT$_2$** than for the 5-HT$_1$ receptor (**K$_i$** of 3500 nM).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

cis-(Z)-Flupentixol dihydrochloride

(cis-(Z)-Flupenthixol dihydrochloride)

Cat. No.: HY-15856

cis-(Z)-Flupentixol dihydrochloride is a potent and selective **DA D1/D2 receptor** antagonist, with **K$_i$** values of 0.38 nM and 7 nM for D2 receptor and **5-HT$_{2A}$**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

cis-Urocanic acid

((Z)-Urocanic acid; cis-UCA)

Cat. No.: HY-113008A

cis-Urocanic acid is a **5-HT2A receptor** agonist. cis-Urocanic acid binds to **5-HT receptor** with relatively high affinity (**K$_d$**=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

cis-Urocanic acid-13C3

((Z)-Urocanic acid-13C3; cis-UCA-13C3)

Cat. No.: HY-113008AS

cis-Urocanic Acid-13C3 ((Z)-Urocanic acid-13C3) is the 13C-labeled cis-Urocanic acid. cis-Urocanic acid is a **5-HT2A receptor** agonist. cis-Urocanic acid binds to **5-HT receptor** with relatively high affinity (**K$_d$**=4.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cisapride

(R 51619; (±)-Cisaprid)

Cat. No.: HY-14149

Cisapride(R 51619) is a nonselective 5-HT4 receptor agonist, it is also a potent hERG potassium channel inhibitor.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

CJ033466

Cat. No.: HY-103108

CJ033466 is a novel and selective **5-HT$_4$ receptor** partial agonist with an **EC$_{50}$** of 9 nM and has gastroprokinetic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clothiapine

Cat. No.: HY-117083

Clothiapine, an atypical antipsychotic agent, shares with clozapine its strong **antiserotonergic** properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP 93129 dihydrochloride

Cat. No.: HY-101357A

CP 93129 dihydrochloride is a potent **5HT$_{1B}$ receptor** agonist. CP 93129 dihydrochloride has the potential for parkinson's disease research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-809101

Cat. No.: HY-15543

CP-809101 is a potent and selective 5-HT2C receptor agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-809101 hydrochloride

Cat. No.: HY-15543A

CP-809101 hydrochloride is a potent and selective 5-HT2C receptor agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CP94253 hydrochloride

Cat. No.: HY-103151

CP94253 hydrochloride is a potent and selective agonist of **5-HT$_{1B}$ receptor** (K_i= 2 nM in a radioligand binding assay).K_i values for 5-HT$_{1A}$, 5-HT$_{1D}$, 5-HT$_{1C}$ and 5-HT$_2$ receptors are 89, 49, 860, and 1600 nM respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Cyamemazine

Cat. No.: HY-14264

Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent **5-HT$_3$** (K_i of 12 nM), **5-HT$_{2A}$** (K_i = 1.5 nM) and **5-HT$_{2C}$** (K_i of 75 nM) receptors antagonist with antipsychotic activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cyamemazine-d6

Cat. No.: HY-14264S

Cyamemazine-d6 is the deuterium labeled Cyamemazine. Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Cyclobenzaprine hydrochloride

(MK130 hydrochloride)

Cat. No.: HY-B0740

Cyclobenzaprine hydrochloride (MK130 hydrochloride) is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Target: 5-HT Receptor 2A Cyclobenzaprine hydrochloride is a skeletal muscle relaxant and a central nervous system (CNS) depressant.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Cyclobenzaprine-13C,d3 hydrochloride

(MK130-13C,d3 hydrochloride)

Cat. No.: HY-B0740S1

Cyclobenzaprine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Cyclobenzaprine-d3 hydrochloride

(MK130-d3 hydrochloride)

Cat. No.: HY-B0740S

Cyclobenzaprine-d3 (MK130-d3) hydrochloride is the deuterium labeled Cyclobenzaprine hydrochloride. Cyclobenzaprine hydrochloride (MK130 hydrochloride) is a skeletal muscle relaxant and a central nervous system (CNS) depressant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 25 mg

Cyclobenzaprine-d6 hydrochloride

(MK130-d6 hydrochloride)

Cat. No.: HY-B0740S2

Cyclobenzaprine-d6 (hydrochloride) is deuterium labeled Cyclobenzaprine (hydrochloride).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Cyproheptadine hydrochloride

Cat. No.: HY-B0366A

Cyproheptadine hydrochloride is a **5-HT$_{2A}$ receptor** antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Cyproheptadine hydrochloride sesquihydrate

Cat. No.: HY-B1165

Cyproheptadine hydrochloride sesquihydrate is an antihistamine and is an antagonist of serotonin and histamine2.



Purity: 99.00%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Dehydroaripiprazole

(OPC-14857; DM-14857)

Cat. No.: HY-100665

Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Dehydroaripiprazole-d8

(OPC-14857-d8; DM-14857-d8)

Cat. No.: HY-100665S

Dehydroaripiprazole-d8 is deuterium labeled Dehydroaripiprazole. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Deramciclane

(EGIS-3886)

Cat. No.: HY-101630

Deramciclane has a high affinity for **5-HT$_{2A}$** and **5-HT$_{2C}$** receptors; it acts as an antagonist at both receptor subtypes and has inverse agonist properties at the 5-HT$_{2C}$ receptors without direct stimulatory agonist.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Desmethyl cariprazine

Cat. No.: HY-100656

Desmethyl cariprazine is an active metabolite of Cariprazine. Cariprazine, an antipsychotic drug candidate, exhibits high affinity for the D3 (K_i=0.085 nM) and D2 (0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (2.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Didesmethyl cariprazine

Cat. No.: HY-100658

Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Dihydroergotamine mesylate

Cat. No.: HY-B0670A

Dihydroergotamine mesylate is an ergot alkaloid used to treat migraines.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dolasetron

(MDL-73147)

Cat. No.: HY-B0750

Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dolasetron Mesylate

(MDL-73147EF)

Cat. No.: HY-B0750A

Dolasetron Mesylate (MDL-73147EF) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dolasetron Mesylate hydrate

(MDL-73147EF hydrate)

Cat. No.: HY-B0750B

Dolasetron Mesylate hydrate (MDL-73147EF hydrate) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.



Purity: 98.73%
Clinical Data: Launched
Size: 100 mg, 200 mg

Dolasetron-d4

(MDL-73147-d4)

Cat. No.: HY-B0750S

Dolasetron-d4 is deuterium labeled Dolasetron.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Donitriptan

Cat. No.: HY-106157

Donitriptan is a potent, high efficacy agonist at **5-HT$_{1B/1D}$ receptor**s with **pK$_i$**s of 9.4 and 9.3, respectively.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DR4485 hydrochloride

Cat. No.: HY-103126

DR4485 (hydrochloride) is an orally active and selective 5-HT$_7$ antagonist (**pK$_i$**=8.14).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DSP-1053

Cat. No.: HY-111419

DSP-1053, a benzylpiperidine derivative, is a potent Serotonin Transporter (SERT) inhibitor with a **K$_i$** of 1.02 nM. DSP-1053 shows partial 5-HT$_{1A}$ receptor agonistic activity with a **K$_i$** of 5.05 nM. DSP-1053 has antidepressant activity.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DSP-1053 benzenesulfonate

Cat. No.: HY-111419A

DSP-1053, a benzylpiperidine derivative, is a potent **serotonin transporter (SERT)** inhibitor with a **K$_i$** of 1.02 nM. DSP-1053 shows partial **5-HT$_{1A}$** receptor agonistic activity with a **K$_i$** of 5.05 nM. DSP-1053 has antidepressant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eletriptan hydrobromide

(Eletriptan HBr)

Cat. No.: HY-A0010

Eletriptan HBr is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively.



Purity: 98.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Eletriptan-d3

Cat. No.: HY-A0039S

Eletriptan-d3 (Eletriptan-d3 HBr) is the deuterium labeled Eletriptan hydrobromide. Eletriptan hydrobromide is a selective 5-HT1B and 5-HT1D receptor agonist with **K$_i$** of 0.92 nM and 3.14 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Eltoprazine

(DU 28853)

Cat. No.: HY-16687

Eltoprazine(DU28853) is a serenic or antiaggressive agent which as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.



Purity: ≥95.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Eltoprazine hydrochloride

(DU 28853 hydrochloride)

Cat. No.: HY-16687A

Eltoprazine hydrochloride (DU 28853 hydrochloride) is a serenic or antiaggressive agent which as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EMD 56551

Cat. No.: HY-19134

EMD 56551 is a potent and selective **5-HT1A receptor** agonist. EMD 56551 exerts anxiolytic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EMDT oxalate

Cat. No.: HY-103098

EMDT oxalate is a selective **5-HT6** agonist, and has antidepressant effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eplivanserin

(SR-46349) Cat. No.: HY-10792

Eplivanserin (SR-46349) is a potent, selective and orally active **5-HT$_{2A}$ receptor** antagonist, with an **IC$_{50}$** of 5.8 nM in rat cortical membrane, and a **K$_d$** of 1.14 nM. Eplivanserin displays >20-fold selectivity more selective for **5-HT$_{2A}$** than 5-HT$_{2B}$ and 5-HT$_{2C}$.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Eplivanserin (mixture)

(SR-46349 (mixture)) Cat. No.: HY-10792A

Eplivanserin mixture (SR-46349 mixture) is a selective **serotonin reuptake** inhibitor and a **5-HT$_{2A}$ receptor** antagonist, extracted from patent WO 2005/002578 A1.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Eplivanserin hemifumarate

(SR-46349 hemifumarate; SR 46349B) Cat. No.: HY-110129

Eplivanserin (SR-46349) hemifumarate is a potent, selective and orally active **5-HT$_{2A}$ receptor** antagonist, with an **IC$_{50}$** of 5.8 nM in rat cortical membrane, and a **K$_d$** of 1.14 nM. Eplivanserin hemifumarate displays >20-fold selectivity more selective for **5-HT$_{2A}$** than 5-HT$_{2B}$ and 5-HT$_{2C}$.



Purity: 98.07%
Clinical Data: Phase 3
Size: 5 mg

Eptapirone

(F 11440) Cat. No.: HY-19946

Eptapirone (F11440) is a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

F-15599

(NLX-101) Cat. No.: HY-19863

F-15599 is a highly selective G-protein biased **5-HT1A receptor** agonist, with **K$_i$** of 3.4 nM.



Purity: 99.61%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

F13714 fumarate

Cat. No.: HY-128901

F13714 fumarate, a selective **5-HT1A receptor** biased agonist, shows antidepressant-like properties after a single administration in the mouse model of chronic mild stress.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Fabesetron

(FK1052 free base) Cat. No.: HY-105201

Fabesetron (FK1052) is an orally active **5-HT$_3$ receptor** antagonist with **5-HT$_4$ receptor** antagonistic activity. Fabesetron (FK1052) can be used in the study for both acute and delayed emesis induced by cancer chemotherapy.



Purity: 95.72%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Facinicline hydrochloride

(RG3487 hydrochloride) Cat. No.: HY-108057A

Facinicline hydrochloride (RG3487 hydrochloride) is an orally active **nicotinic α7 receptor** partial agonist, with a **K$_i$** of 6 nM for α7 human nAChR. Facinicline hydrochloride (RG3487 hydrochloride) improves cognition and sensorimotor gating in rodents.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fananserin

(RP 62203) Cat. No.: HY-103104

Fananserin (RP 62203) is an orally bioavailable, potent and selective **5-hydroxytryptamine2 (5-HT$_2$)** receptor antagonist, with a **K$_i$** of 0.37 nM for the rat 5-HT$_{2A}$ receptor.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Felcisetrag

(TD-8954) Cat. No.: HY-102057

Felcisetrag (TD-8954) is an orally active, potent and selective **5-HT$_4$** receptor agonist with gastrointestinal prokinetic properties. Felcisetrag has high affinity (**pK$_i$** =9.4) for **human 5-HT$_{4(c)}$** receptors.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Flesinoxan

Cat. No.: HY-121653

Flesinoxan is a hypotensive agent and a potent, high affinity and selective **5-hydroxytryptamine1A (5-HT1A) receptor** agonist with an **EC_{50}** value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Flibanserin

(BIMT-17; BIMT-17BS)

Cat. No.: HY-A0095

Flibanserin (BIMT-17) is a full agonist of the serotonin **5-HT1A receptor** (K_i=1 nM) and an antagonist of **5-HT2A** (49 nM).



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Flibanserin-d4

(BIMT-17-d4; BIMT-17BS-d4)

Cat. No.: HY-A0095S

Flibanserin D4 is a deuterium labeled Flibanserin (BIMT-17). Flibanserin is a full agonist of the serotonin 5-HT1A receptor (K_i=1 nM) and an antagonist of 5-HT2A (49 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flibanserin-d4-1

(BIMT-17-d4-1; BIMT-17BS-d4-1)

Cat. No.: HY-A0095S1

Flibanserin-d4-1 is deuterium labeled Flibanserin. Flibanserin (BIMT-17) is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flopropione

Cat. No.: HY-100562

Flopropione is a **5-HT receptor** antagonist and also a **catechol-o-methyltransferase (COMT)** inhibitor. Flopropione also as an antispasmodic agent.



Purity: 98.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Flumexadol

Cat. No.: HY-133024

Flumexadol is a selective and affinity **5-HT_{2C} receptor** agonist with a K_i of 25 nM for the (+)-enantiomer of Flumexadol, and is 40-fold selective over the 5-HT_{2A} receptor. Flumexadol is an orally active non-narcotic analgesic.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

FPPQ

Cat. No.: HY-115724

FPPQ is a dual-acting 5-HT_3 (K_i = 0.9 nM) and 5-HT_6 (K_i = 3 nM) receptor antagonist with antipsychotic and procognitive properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Frovatriptan

((R)-Frovatriptan; SB 209509; VML 251)

Cat. No.: HY-B1658

Frovatriptan is a potent **$5\text{-HT}_{1B/D}$** receptor agonist and has the highest 5-HT_{1B} potency in the triptan class. Frovatriptan is apparently cerebroselective.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Frovatriptan succinate ((R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate)

Cat. No.: HY-B1658B

Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active **5-HT_{1B}** (**pK_{50}** of 8.2) and **5-HT_{1D} receptor** agonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; ...)

Cat. No.: HY-B1658A

Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active **5-HT_{1B}** (**pK_{50}** of 8.2) and **5-HT_{1D} receptor** agonist.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg

Frovatriptan-d3 succinate ((R)-Frovatriptan-d3 succinate; SB 209509-d3 succinate; VML 251-d3 succinate)

Cat. No.: HY-B1658BS

Frovatriptan-d3 (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gamma-Mangostin (γ-Mangostin)

Cat. No.: HY-N1957

Gamma-Mangostin is a novel competitive **5-hydroxytryptamine 2A (5-HT2A) receptors** antagonist, purified from the fruit hull of the medicinal plant Garcinia mangostana.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Geissoschizine methyl ether

Cat. No.: HY-N2411

Geissoschizine methyl ether, a major indole alkaloid found in **Uncaria** hook, is a major active component of Yokukansan with psychotropic effects. Geissoschizine methyl ether is potent **5-HT$_{1A}$ receptor** agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gentisein (NSC 329491; 1,3,7-Trihydroxyxanthone)

Cat. No.: HY-118166

Gentisein (NSC 329491), the major metabolite of Mangiferin, shows the most potent serotonin uptake inhibition with an IC_{50} value of 4.7 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GR 113808

Cat. No.: HY-103152

GR 113808 is a potent and highly selective **5-HT$_4$ receptor** antagonist (**pK$_b$**= 8.8). GR 113808 shows 300-fold selectivity over 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{2A}$, 5-HT$_{2C}$ and 5-HT$_3$ receptors.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

GR 125743

Cat. No.: HY-121392

GR 125743 is a selective **5-HT$_{1B/1D}$** receptor antagonist, with **pK$_i$**s of 8.85 and 8.31 for wild-type h5-HT$_{1B}$ and wild-type h5-HT$_{1D}$, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Granisetron (BRL 43694)

Cat. No.: HY-B0071

Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Granisetron Hydrochloride (BRL 43694A)

Cat. No.: HY-B0071A

Granisetron (Hydrochloride) (BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Granisetron-d3

Cat. No.: HY-132348S

Granisetron-d3 (BRL 43694-d3) is the deuterium labeled Granisetron. Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

GSK163090

Cat. No.: HY-14348

GSK163090 is a potent, selective and orally active **5-HT$_{1A/1B/1D}$ receptor** antagonist with **pK$_i$** values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a **pK$_i$** value of 6.1.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GTS-21 dihydrochloride

(DMXB-A; DMBX-anabaseine) Cat. No.: HY-14564A

GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor **(α7-nAChR)** agonist with antiinflammatory and cognitionenhancing activities.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Harmine hydrochloride

(Telepathine hydrochloride) Cat. No.: HY-N0737

Harmine Hydrochloride (Telepathine Hydrochloride) is a natural **DYRK** inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of **5-HT$_{2A}$ serotonin receptor**, with an **K$_i$** of 397 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Hydroxy ziprasidone

Cat. No.: HY-100649

Hydroxy ziprasidone is an impurity of Ziprasidone. Ziprasidone, an antipsychotic agent, is a combined 5-HT (serotonin) and dopamine receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxy ziprasidone-d8

Cat. No.: HY-100649S

Hydroxy Ziprasidone-d8 is the deuterium labeled Hydroxy ziprasidone. Hydroxy ziprasidone is an impurity of Ziprasidone. Ziprasidone, an antipsychotic agent, is a combined 5-HT (serotonin) and dopamine receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypidone hydrochloride

(YL0919) Cat. No.: HY-100769

Hypidone hydrochloride (YL0919) is an orally active antidepressant agent with dual activity as a highly seletive **5-HT uptake** blocker and an effective **5-HT$_{1A}$ receptor** agonist (**K$_i$**=0.19 nM).



Purity: 99.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Idalopirdine

(Lu AE58054) Cat. No.: HY-14338

Idalopirdine (Lu AE58054) is a potent and selective **5-HT6 receptor** antagonist with a **K$_i$** of 0.83 nM.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Idalopirdine Hydrochloride

(Lu AE58054 Hydrochloride) Cat. No.: HY-14338A

Idalopirdine Hydrochloride (Lu AE58054 Hydrochloride) is a potent and selective **5-HT6 receptor** antagonist with a **K$_i$** of 0.83 nM.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Iferanserin

(S-MPEC) Cat. No.: HY-118557

Iferanserin (S-MPEC) is a selective **5-HT receptor** (**serotonin receptor**) antagonist with an affinity for **5-HT$_{2A}$ receptor**. Iferanserin has the potential for internal hemorrhoid disease treatment.



Purity: 99.74%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iloperidone

(HP 873) Cat. No.: HY-17410

Iloperidone (HP 873) is a **D$_2$/5-HT$_2$** receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Iloperidone hydrochloride

(HP 873 hydrochloride) Cat. No.: HY-17410A

Iloperidone hydrochloride (HP 873 hydrochloride) is a **D$_2$/5-HT$_2$** receptor antagonist. Iloperidone hydrochloride is an atypical antipsychotic for the schizophrenia symptoms.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Iloperidone-d3

Cat. No.: HY-17410S

Iloperidone-d3 is the deuterium labeled Iloperidone. Iloperidone (HP 873) is a **D_2/5-HT_2** receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 100 mg

Indophagolin

Cat. No.: HY-134807

Indophagolin is a potent, indoline-containing **autophagy** inhibitor (IC_{50}=140 nM). Indophagolin antagonizes the purinergic receptor **$P2X_4$** as well as $P2X_1$ and $P2X_3$ with IC_{50}s of 2.71, 2.40 and 3.49 μM, respectively.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Intepirdine

(SB-742457; GSK-742457; RVT-101)

Cat. No.: HY-14339

Intepirdine (SB742457) is a highly selective 5-HT6 receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.



Purity: 98.92%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iprindole

Cat. No.: HY-12392

Iprindole, a tricyclic indole antidepressant, is a weak inhibitor of the uptake of noradrenaline and 5-HT.
.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Ipsapirone

(TVX Q 7821 free base)

Cat. No.: HY-19686

Ipsapirone (TVX Q 7821) is an anxiolytic compound and a **5-HT_{1A}** receptor partial agonist. Ipsapirone (TVX Q 7821) also exhibits **5-HT_{1A}** receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT_2 and the α_1-adrenergic function.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg

Irindalone

(Lu 21-098)

Cat. No.: HY-101632

Irindalone is a novel serotonin **5-HT_2** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isamoltane hemifumarate

Cat. No.: HY-19578B

Isamoltane hemifumarate is a selective antagonist of **5-HT_{1B} receptor**, with an **IC_{50}** of 39 nM for inhibits the binding of [^{125}I]ICYP to 5-HT_{1B} recognition sites in rat brain membranes. Isamoltane hemifumarate is also a **β-adrenoceptor** ligand, with an **IC_{50}** of 8.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Isocorynoxeine

(7-Isocorynoxeine)

Cat. No.: HY-N0775

Isocorynoxeine, an isorhynchophylline-related alkaloid, exhibits a dose-dependent inhibition of **5-HT_{2A}** receptor-mediated current response with an **IC_{50}** of 72.4 μM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isopteropodine

Cat. No.: HY-N4157

Isopteropodine is heteroyohimbine-type oxindole alkaloid components of Uncaria tomentosa (Willd.) DC. Isopteropodine acts as positive modulators of **muscarinic M1** and **5-HT2** receptors.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 5 mg

Jatrorrhizine

Cat. No.: HY-N0749

Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Jatrorrhizine chloride

Cat. No.: HY-N0740

Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Jatrorrhizine hydroxide

Cat. No.: HY-N0749A

Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JNJ-18038683

Cat. No.: HY-19889

JNJ-18038683 is a 5-Hydroxytryptamine Type 7 (**5-HT$_7$**) receptor antagonist, with **pK$_i$s** of 8.19, 8.20 for rat and human 5-HT$_7$ in HEK293 cells, respectively.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ketanserin

(R41468)

Cat. No.: HY-10562

Ketanserin is a selective **5-HT2 receptor** antagonist. Ketanserin also blocks hERG current (**I$_{hERG}$**) in a concentration-dependent manner (**IC$_{50}$**=0.11 μM).



Purity: 99.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Ketanserin tartrate

(R41468 tartrate)

Cat. No.: HY-10562A

Ketanserin (R41468) tartrate is a selective **5-HT2 receptor** antagonist. Ketanserin tartrate also blocks hERG current (**I$_{hERG}$**) in a concentration-dependent manner (**IC$_{50}$**=0.11 μM).



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Keto Ziprasidone

Cat. No.: HY-100648

Keto Ziprasidone is an impurity of Ziprasidone. Ziprasidone, an antipsychotic agent, is a combined 5-HT (serotonin) and dopamine receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Latrepirdine dihydrochloride

(Dimebolin dihydrochloride)

Cat. No.: HY-14537

Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and **amyloid-β** (**Aβ**) secretion.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

LE 300

Cat. No.: HY-103428

LE 300 is a potent and selective **dopamine D1-like receptor** antagonist with **K$_i$**s of 1.9 nM and 7.5 nM in CHO cell membranes expressing human dopamine D1 and D5 receptors, respectively. LE 300 is an antagonist of the 5-HT$_{2A}$ receptor with a pA2 of 8.32 in a rat tail artery assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lerisetron

Cat. No.: HY-105090

Lerisetron is a potent **5-HT$_3$** antagonists and possess high-affinity binding for the 5-HT$_3$ receptors with **pK$_i$** value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lesopitron dihydrochloride

(E4424)

Cat. No.: HY-101609

Lesopitron dihydrochloride is a full and selective **5-HT$_{1A}$** receptor agonist with **IC$_{50}$** of 125 nM in rat hippocampal membranes.



Purity: 96.67%
Clinical Data: No Development Reported
Size: 5 mg

Levomepromazine
(Methotrimeprazine) **Cat. No.:** HY-B1693

Levomepromazine (Methotrimeprazine) is an orally available neuroleptic agent, which is commonly used to relieve nausea and vomiting in palliative care settings.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Lidanserin
(ZK-33839) **Cat. No.:** HY-101815

Lidanserin (ZK-33839) acts as a **5-HT$_{2A}$** and **α_1-adrenergic receptor** antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Lidanserin-d6
(ZK-33839-d6) **Cat. No.:** HY-101815S

Lidanserin-d6 (ZK-33839-d6) is the deuterium labeled Lidanserin. Lidanserin (ZK-33839) acts as a **5-HT$_{2A}$** and **α_1-adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lintopride
Cat. No.: HY-U00121

Lintopride is a **5HT4** antagonist with moderate 5HT3 antagonist properties.



Purity: 96.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Loxapine
Cat. No.: HY-17390

Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Loxapine succinate
Cat. No.: HY-17390A

Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Loxapine-d8 hydrochloride
Cat. No.: HY-17390BS

Loxapine-d8 hydrochloride is the deuterium labeled Loxapine. Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

LP 12 hydrochloride
Cat. No.: HY-103105

LP 12 hydrochloride (compound 21) is a potent and selective **5-HT7 receptor** agonist with a **K$_i$** of 0.13 nM. LP 12 hydrochloride displays selectivity for 5-HT7 over D2, 5-HT1A and 5-HT2A receptors (**K$_i$** values are 224 nM, 60.9 nM and >1000 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LP-211
Cat. No.: HY-111455

LP-211 is a selective and blood–brain barrier penetrant **5-HT$_7$ receptor** agonist, with a **K$_i$** of 0.58 nM, with high selectivity over 5-HT$_{1A}$ receptor (K$_i$, 188 nM) and D$_2$ receptor (K$_i$, 142 nM).



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

LP44 hydrochloride
Cat. No.: HY-103101

LP44 (hydrochloride) is a selective **5-HT7** agonist with **Ki** of 0.22 nM. LP44 (hydrochloride) induces hypothermic effect in a dose-dependent manner by intracerebroventricular injection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lumateperone tosylate

(ITI-007 tosylate) Cat. No.: HY-19733

Lumateperone tosylate (ITI-007 tosylate) is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM).



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lurasidone

(SM-13496) Cat. No.: HY-B0032A

Lurasidone (SM-13496) is an antagonist of both **dopamine D_2** and **5-HT_7** with **IC_{50}**s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of **5-HT_{1A}** receptor with an **IC_{50}** of 6.75 nM.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Lurasidone Hydrochloride

(SM-13496 Hydrochloride) Cat. No.: HY-B0032

Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both **dopamine D_2** and **5-HT_7** with **IC_{50}**s of 1.68 and 0.495 nM, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Lurasidone-d8

(SM-13496-d8) Cat. No.: HY-B0032AS

Lurasidone-d8 is deuterium labeled Lurasidone. Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lurasidone-d8 hydrochloride

(SM-13496-d8 hydrochloride) Cat. No.: HY-B0032S

Lurasidone-d8 (SM-13496-d8) hydrochloride is the deuterium labeled Lurasidone, which is an inhibitor of Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 344864

Cat. No.: HY-13788

LY 344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. IC50 Value: 6 nM (Ki) Target: 5-HT1F LY 344864 possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined .



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY 344864 hydrochloride

Cat. No.: HY-13788B

LY 344864 hydrochloride is a selective **5-HT1F** agonist with a **K_i** of 6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 344864 racemate

Cat. No.: HY-13788C

LY 344864 racemate is a **5-HT_{1F} receptor** agonist extracted from patent US 5708187 A.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY 344864 S-enantiomer

Cat. No.: HY-13788A

LY 344864 S-enantiomer is the S-enantiomer of LY344864. LY344864 is a 5-HT1F receptor agonist.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

LY-272015 hydrochloride

Cat. No.: HY-100851A

LY-272015 hydrochloride is an orally active, specific **5-HT_{2B} receptor** antagonist. LY-272015 hydrochloride completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY266097 hydrochloride

Cat. No.: HY-103094

LY266097 hydrochloride is a selective **5-HT2B** receptor antagonist with **pK$_i$**s of 7.7, 9.8, and 7.6 for **5-HT2A**, **5-HT2B**, **5-HT2C**, respectively. 5-HT2B receptor blockade contributes to the research in depression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY310762

Cat. No.: HY-13527

LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM, having a weaker affinity for 5-HT1B receptor. IC50 value: 249 nM (Ki) Target: 5-HT1D in vitro: LY310762 has a higher affinity for the guinea pig 5-HT1D receptor than for the 5-HT1B receptor.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

LY320135

Cat. No.: HY-W011040

LY320135 is a potent and selective antagonist of **CB1** receptor, with a **K$_i$** of 141 nM. LY320135 also binds to **5-HT$_2$** and **muscarinic receptors** with **K$_i$**s of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY334370

Cat. No.: HY-103107

LY334370 is a selective **5-HT$_{1F}$** receptor agonist with a **K$_i$** of 1.6 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY393558

Cat. No.: HY-103089

LY393558 is a potent and orally active inhibitor of the **5-HT** transporter and an antagonist of **5-HT1B** and **5-HT1D** receptors. LY393558 increase the extracellular levels of **5-HT** in mice model frontal cortex. LY393558 can be used for researching depression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Masupirdine free base

(SUVN-502 free base)

Cat. No.: HY-109118

Masupirdine free base (SUVN-502 free base) is a potent, selective, orally bioavailable, and brain penetrant **5-HT6 receptor** antagonist (**K$_i$** of 2.04 nM for human 5-HT6 receptor).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Masupirdine mesylate

(SUVN-502 mesylate)

Cat. No.: HY-109118A

Masupirdine mesylate (SUVN-502 mesylate) is a potent, selective, orally bioavailable, and brain penetrant **5-HT6 receptor** antagonist (**K$_i$** of 2.04 nM for human 5-HT6 receptor).



Purity: >98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg

Melitracen hydrochloride

Cat. No.: HY-108256

Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and **5-HT (serotonin)** through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space.



Purity: 99.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Melitracen-d6 hydrochloride

Cat. No.: HY-108256S

Melitracen-d6 hydrochloride is the deuterium labeled Melitracen hydrochloride. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Mesembrine

((+)-Mesembrine)

Cat. No.: HY-121162

Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a **5-HT transporter** inhibitor with a **K$_i$** of 1.4 nM. Mesembrine also inhibits **phosphodiesterase 4B (PDE4B)** with an **IC$_{50}$** of 7.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Mesembrine-d3

Cat. No.: HY-121162S

Mesembrine-d3 ((+)-Mesembrine-d3) is the deuterium labeled Mesembrine. Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a **5-HT transporter** inhibitor with a K_i of 1.4 nM.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Metergoline

Cat. No.: HY-B1033

Metergoline is a **serotonin (5-HT) receptor** and **dopamine receptors** antagonist, with **pK_i**s of 8.64, 8.75 and 8.75 for 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C}, respectively. Metergoline is a high-affinity ligand for the h5-HT_7 receptor, with a K_i of 16 nM.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Metergoline-d5

Cat. No.: HY-B1033S

Metergoline-d5 is the deuterium labeled Metergoline. Metergoline is a **serotonin (5-HT) receptor** and **dopamine receptors** antagonist, with **pK_i**s of 8.64, 8.75 and 8.75 for 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methiothepin mesylate

(Metitepine mesylate; Ro 8-6837 mesylate)

Cat. No.: HY-107836

Methiothepin mesylate is a potent and non-selective **5-HT_2 receptor** antagonist, with pK_ds of 7.10 (5-HT_{1A}), 7.28 ($5HT_{1B}$), 7.56 ($5HT_{1C}$), 6.99 ($5HT_{1D}$), 7.0 (5-HT_{5A}), 7.8 (5-HT_{5B}), 8.74 (5-HT_6), and 8.99 (5-HT_7), and pK_is of 8.50 ($5HT_{2A}$), 8.68 ($5HT_{2B}$), and...



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

MHP 133

Cat. No.: HY-101653

MHP 133 is a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with K_i of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mirtazapine

(Org3770; 6-Azamianserin)

Cat. No.: HY-B0352

Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent. Mirtazapine is also a **5-HT_2**, **5-HT_3**, **histamine H1 receptor** and **α2-adrenoceptor** antagonist with **pK_i** values of 8.05, 8.1, 9.3 and 6.95, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Mirtazapine D3

(Org3770 D3; 6-Azamianserin D3)

Cat. No.: HY-B0352S

Mirtazapine D3 (Org3770 D3; 6-Azamianserin D3) is a deuterium labeled Mirtazapine. Mirtazapine is a **5-HT receptor** inhibitor. Mirtazapine is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent by blocking 5-HT2 and 5-HT3 receptors.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mirtazapine-d4

(Org3770-d4; 6-Azamianserin-d4)

Cat. No.: HY-B0352S2

Mirtazapine-d4 is deuterium labeled Mirtazapine. Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-212

(CPP)

Cat. No.: HY-101324

MK-212 (CPP) is a centrally acting **5-HT_{1C}/5-HT_2** agonist. MK-212 can stimulate phosphoinositide hydrolysis in cerebral cortex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-212 monohydrochloride

(CPP monohydrochloride)

Cat. No.: HY-101324A

MK-212 (CPP) monohydrochloride is a centrally acting **5-HT_{1C}/5-HT_2** agonist. MK-212 monohydrochloride can stimulate phosphoinositide hydrolysis in cerebral cortex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML 10302

Cat. No.: HY-14441

ML 10302 is a potent agonist **5-HT4** receptor with K_i of 1.07 nM. 5-Hydroxytryptamine (5-HT4) receptor agonists stimulate gut motility through cholinergic pathways. ML10302 induces significant prokinesia both in the small bowel and colon through activation of cholinergic pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML 10302 hydrochloride

Cat. No.: HY-14442

ML 10302 hydrochloride is a potent and selective **5-HT_4 receptor** agonist, with an **EC_{50}** of 4 nM. ML 10302 hydrochloride displays more than 680-fold selectivity over **5-HT_3** receptor in binding assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MM 77 dihydrochloride

Cat. No.: HY-101322A

MM 77 dihydrochloride is a potent postsynaptic antagonist of the **5-HT_{1A} receptor**. MM 77 dihydrochloride exhibits anxiolytic-like activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mosapride

(TAK-370; AS-4370)

Cat. No.: HY-B0189

Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. Target: 5HT4 Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Mosapride citrate

(TAK-370 citrate; AS-4370 citrate)

Cat. No.: HY-B0189A

Mosapride citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist. Target: 5HT4 Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Mosapride-d5

Cat. No.: HY-B0189S1

Mosapride-d5 is the deuterium labeled Mosapride. Mosapride is a gastroprokinetic agent that acts as a selective 5HT_4 agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Mosapride-d5 citric amide

Cat. No.: HY-B0189AS

Mosapride-d5 citric amide is the deuterium labeled Mosapride citrate. Mosapride citrate is a gastroprokinetic agent that acts as a selective 5HT_4 agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Mosapride-d5 N-Oxide

Cat. No.: HY-B0189S

Mosapride-d5 N-Oxide is the deuterium labeled Mosapride. Mosapride is a gastroprokinetic agent that acts as a selective 5HT_4 agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

MS 245 oxalate

Cat. No.: HY-103113

MS 245 oxalate is a potent antagonist of **5-HT_6** receptor with a K_i of 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Myristicin

(Myristicine)

Cat. No.: HY-N2510

Myristicine act as a serotonin receptor antagonist, a weak **monamine oxidase (MAO)** inhibitor. Myristicine is the main component of nutmeg essential oil from Myristica fragrans Houtt.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Naftidrofuryl oxalate

(Nafronyl oxalate salt) Cat. No.: HY-B1107

Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.



Purity: 96.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Naluzotan

(PRX 00023) Cat. No.: HY-14848

Naluzotan is a novel, potent, and selective amidosulfonamide **5-HT1A** agonist with **IC_{50}** and **K_i** of appr 20 nM and 5.1 nM, used for the treatment of anxiety and depression; Also a weak **hERG K^+ channel** blocker, with IC_{50} of 3800 nM.



Purity: 98.05%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

NAN-190 hydrobromide

Cat. No.: HY-19818A

NAN-190 hydrobromide is a serotonin receptor **5-HT** antagonist. NAN-190 is a selective antagonist of **5-HT_{1A}**.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Naratriptan

(GR-85548A) Cat. No.: HY-B0197

Naratriptan is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches. Target: 5-HT1 Receptor Naratriptan is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Naratriptan D3 Hydrochloride

(GR-85548A D3) Cat. No.: HY-B0197AS

Naratriptan D3 Hydrochloride is the deuterium labeled Naratriptan, which is a selective 5-HT1 receptor subtype agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naratriptan hydrochloride

(GR-85548A hydrochloride) Cat. No.: HY-B0197A

Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Naronapride

(ATI-7505) Cat. No.: HY-121826

Naronapride (ATI-7505) is a potent prokinetic **5-HT_4 receptor** agonist. Naronapride can be used for gastrointestinal diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NAS181

Cat. No.: HY-103156

NAS181 is a potent and selective antagonist of **rat 5-HT_{1B}** receptor, with a **K_i** of 47 nM. NAS181 shows 13-fold selectivity for $r5\text{-HT}_{1B}$ over bovine 5-HT_{1B} receptor (K_i=630 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nefazodone hydrochloride

(BMY-13754; MJ-13754-1) Cat. No.: HY-B1396

Nefazodone hydrochloride (BMY-13754) is a potent and selective **5HT2A** (**K_i**=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (**IC_{50}** of 290 and 300 nM, respectively).



Purity: 99.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Nefazodone-d6 dihydrochloride (BMY-13754-d6 dihydrochloride; MJ-13754-1-d6 dihydrochloride)

Cat. No.: HY-B1396S1

Nefazodone-d6 (dihydrochloride) is deuterium labeled Nefazodone (hydrochloride).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nefazodone-d6 hydrochloride

(BMY-13754-d6; MJ-13754-1-d6) Cat. No.: HY-B1396S

Nefazodone-d6 hydrochloride (BMY-13754-d6) is the deuterium labeled Nefazodone hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nelotanserin

(APD125) Cat. No.: HY-10559

Nelotanserin is a potent **5-HT$_{2A}$** inverse agonist, a moderately potent **5-HT$_{2C}$** partial inverse agonist and a weak **5-HT$_{2B}$** inverse agonist, with **IC$_{50}$s** of 1.7, 79, 791 nM in IP accumulation assays, respectively.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nemifitide diTFA

(INN 00835 diTFA) Cat. No.: HY-105077A

Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action. Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF). Nemifitide diTFA can cross the blood-brain barrier.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nemonapride

(YM-09151-2; Emilace; Emonapride) Cat. No.: HY-103415

Nemonapride is a highly potent **dopamine D$_2$ receptor** antagonist with a **K$_i$** of 0.06 nM. Nemonapride also activates **5-HT$_{1A}$ receptor** with an **IC$_{50}$** of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NEO 376

(SPI-376) Cat. No.: HY-101583

NEO 376 is a selective modulator of **5-HT1 receptor**, **GABA receptor** and **dopamine receptor**, with anti-psychotic actively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Nexopamil racemate

Cat. No.: HY-101727

Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined **Ca^{2+}/5-HT$_2$** antagonist on thrombus formation in vivo and on platelet aggregation in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NPS ALX Compound 4a

Cat. No.: HY-103090

NPS ALX Compound 4a is a potent and selective **5-hydroxytryptamine$_6$ (5-HT$_6$) receptor** antagonist, with an **IC$_{50}$** of 7.2 nM and a **K$_i$** of 0.2 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

NPS ALX Compound 4a dihydrochloride

Cat. No.: HY-103090A

NPS ALX Compound 4a dihydrochloride is a potent and selective **5-hydroxytryptamine$_6$ (5-HT$_6$) receptor** antagonist, with an **IC$_{50}$** of 7.2 nM and a **K$_i$** of 0.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRA-0160

Cat. No.: HY-101641

NRA-0160 is a selective **dopamine D4 receptor** antagonist, with a **K$_i$** value of 0.48 nM and with negligible affinity for **dopamine D2 receptor** (**K$_i$**: >10000 nM), **D3 receptor** (**K$_i$**: 39 nM), rat **5-HT2A receptor** (**K$_i$**: 180 nM) and rat **α1 adrenoceptor** (**K$_i$**: 237 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nuciferine

Cat. No.: HY-N0049

Nuciferine is an antagonist at **5-HT$_{2A}$** (**IC$_{50}$**=478 nM), **5-HT$_{2C}$** (**IC$_{50}$**=131 nM), and **5-HT$_{2B}$** (**IC$_{50}$**=1 μM), an inverse agonist at **5-HT$_7$** (**IC$_{50}$**=150 nM), a partial agonist at **D$_2$** (**EC$_{50}$**=64 nM), **D$_5$** (**EC$_{50}$**=2.6 μM) and **5-HT$_6$** (**EC$_{50}$**=700 nM), an agonist at **5-HT$_{1A}$** (**EC$_{50}$**=3.2 μM) and...



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Ocaperidone

(R79598) Cat. No.: HY-101094

Ocaperidone is an effective antipsychotic agent, acting as a potent **5-HT$_2$** and **dopamine D$_2$** antagonist, and a **5-HT$_{1A}$** agonist, with **K$_i$**s of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT$_2$, a$_1$-adrenergic receptor, dopamine D$_2$, histamine H$_1$ and a$_2$-adrenergic...



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ondansetron

(GR 38032; SN 307) Cat. No.: HY-B0002B

Ondansetron(GR 38032; SN 307) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ondansetron hydrochloride

(GR 38032 hydrochloride; SN 307 hydrochloride) Cat. No.: HY-B0002

Ondansetron hydrochloride (GR 38032 hydrochloride; SN 307 hydrochloride) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ondansetron hydrochloride dihydrate (GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate)

Cat. No.: HY-B0002A

Ondansetron hydrochloride dihydrate (GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.



Purity: 99.03%
Clinical Data: Launched
Size: 50 mg, 100 mg, 1 g, 5 g

Ondansetron-13C,d3

(GR 38032-13C,d3; SN 307-13C,d3) Cat. No.: HY-B0002BS2

Ondansetron-13C,d3 is the 13C- and deuterium labeled.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ondansetron-d3 hydrochloride

Cat. No.: HY-B0002S

Ondansetron-d3 (GR 38032-d3) hydrochloride) is the deuterium labeled Ondansetron hydrochloride. Ondansetron hydrochloride (GR 38032 hydrochloride) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Ondansetron-d5

(GR 38032-d5; SN 307-d5) Cat. No.: HY-B0002BS

Ondansetron-d5 (GR 38032-d5) is the deuterium labeled Ondansetron. Ondansetron (GR 38032; SN 307) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OPC-14523 free base

Cat. No.: HY-116594

OPC-14523 free base is an orally active **sigma** and **5-HT1A receptor** agonist, with high affinity for sigma receptors (σ1/2 **IC$_{50}$**=47/56 nM), the 5-HT1A receptor (**IC$_{50}$**=2.3 nM), and the 5-HT transporter (**IC$_{50}$**=80 nM). OPC-14523 free base shows antidepressant-like activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OPC-14523 hydrochloride

Cat. No.: HY-116594A

OPC-14523 hydrochloride is an orally active **sigma** and **5-HT1A receptor** agonist, with high affinity for sigma receptors (σ1/2 **IC$_{50}$**=47/56 nM), the 5-HT1A receptor (**IC$_{50}$**=2.3 nM), and the 5-HT transporter (**IC$_{50}$**=80 nM). OPC-14523 hydrochloride shows antidepressant-like activity.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Opiranserin

(VVZ-149) Cat. No.: HY-109067

Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of **glycine transporter type 2 (GlyT2)** and **serotonin receptor 2A (5HT2A)**, with **IC$_{50}$**s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC$_{50}$=0.87 μM).



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Opiranserin hydrochloride

(VVZ-149 hydrochloride)

Cat. No.: HY-109067A

Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of **glycine transporter type 2 (GlyT2)** and **serotonin receptor 2A (5HT2A)**, with IC_{50}s of 0.86 and 1.3 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Org-12962

Cat. No.: HY-118152

Org-12962 is a potent, selective and orally active **5-HT_{2C} receptor** agonist with a **pEC_{50}** value of 7.01. Org-12962 also exhibits high efficacy for the 5-HT_{2A} and 5-HT_{2B} receptor with **pEC_{50}**s of 6.38 and 6.28, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Org-12962 hydrochloride

Cat. No.: HY-21994

Org 12962 hydrochloride is a potent, selective and efficacious 5-HT_{2C} receptor agonist and exhibits **pEC_{50}** values of 7.01, 6.38 and 6.28 for 5-HT_{2C}, 5-HT_{2A} and 5-HT_{2A}, respectively. Org 12962 hydrochloride is effective in panic-like anxiety animal model.</br>.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Org37684

Cat. No.: HY-103120

Org37684 is a highly potent **5-HT_{2C} receptor** agonist (**pEC_{50}**=8.17). Org37684 exhibits a rank order of potency of 5-HT_{2C}>5-HT_{2B}>5-HT_{2A}.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxatomide

Cat. No.: HY-123205

Oxatomide is a potent and orally active dual **H1-histamine receptor** and **P2X7 receptor** antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in **human P2X7 receptors** (IC_{50} of 0.95 μM).



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

p-MPPI hydrochloride

Cat. No.: HY-120738

p-MPPI hydrochloride is a selective **5-HT1A receptor** antagonist with high affinity for 5-HT1A receptors. p-MPPI hydrochloride can crosses the blood-brain barrier, and has clear antidepressant and anxiolytic-like effects.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Paliperidone

(9-Hydroxyrisperidone)

Cat. No.: HY-A0019

Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a **dopamine D2** antagonist and **5-HT2A** antagonist. Paliperidone is also active as an antagonist at **α1** and **α2 adrenergic** receptors and **H1-histaminergic** receptors.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Paliperidone palmitate

(9-Hydroxyrisperidone palmitate)

Cat. No.: HY-A0019A

Paliperidone palmitate (9-Hydroxyrisperidone palmitate), an atypical long-acting antipsychotic agent, is an ester prodrug of Paliperidone. Paliperidone is a **dopamine** antagonist and **5-HT2A** antagonist of the atypical antipsychotic class.



Purity: 98.41%
Clinical Data: Launched
Size: 10 mg

Paliperidone-d4

Cat. No.: HY-A0019S

Paliperidone-d4 is the deuterium labeled Paliperidone. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a **dopamine D2** antagonist and **5-HT2A** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palonosetron

Cat. No.: HY-A0018

Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Palonosetron hydrochloride

Cat. No.: HY-A0021

Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Palonosetron-d3 hydrochloride

Cat. No.: HY-A0021S

Palonosetron-d3 hydrochloride is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Pancopride

(LAS 30451)

Cat. No.: HY-19684

Pancopride is a new potent and selective **5-HT$_3$ receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pardoprunox

(SLV-308; DU-126891)

Cat. No.: HY-14958

Pardoprunox (SLV-308) is a partial **dopamine D2** and **D3 receptor** partial agonist and a **serotonin 5-HT1A receptor** agonist, with **pEC$_{50}$**s of 8, 9.2, and 6.3, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Pardoprunox hydrochloride

(SLV-308 hydrochloride; DU-126891 hydrochloride)

Cat. No.: HY-14958A

Pardoprunox (SLV-308) hydrochloride is a partial **dopamine D2** and **D3 receptor** partial agonist and a **serotonin 5-HT1A receptor** agonist, with **pEC$_{50}$**s of 8, 9.2, and 6.3, respectively.



Purity: 98.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PCPA methyl ester hydrochloride

(4-Chloro-DL-phenylalanine methyl ester hydrochloride)

Cat. No.: HY-101456

PCPA methyl ester hydrochloride (4-Chloro-DL-phenylalanine methyl ester hydrochloride), a reversible **tryptophan hydroxylase** inhibitor, is a **serotonin (5-HT) synthesis** inhibitor.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 g

Peptide 401

Cat. No.: HY-12537

Peptide 401, a potent mast cell degranulating factor from bee venom, suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (**histamine**, and **5-HT**).

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Perospirone

(SM-9018 free base)

Cat. No.: HY-B0731A

Perospirone (SM-9018 free base) is an orally active antagonist of **5-HT$_{2A}$** receptor (**K$_i$**=0.6 nM) and **dopamine D$_2$** receptor (**K$_i$**=1.4 nM), and also a partial agonist of **5-HT$_{1A}$** receptor (**K$_i$**=2.9 nM).



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Perospirone hydrochloride

(SM-9018)

Cat. No.: HY-B0731

Perospirone hydrochloride (SM-9018) is an orally active antagonist of **5-HT$_{2A}$** receptor (**K$_i$** of 0.6 nM) and **dopamine D$_2$** receptor (**K$_i$** of 1.4 nM). Perospirone hydrochloride is also a partial agonist of **5-HT$_{1A}$** receptor (**K$_i$** of 2.9 nM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Perphenazine

Cat. No.: HY-A0077

Perphenazine is a typical antipsychotic drug, inhibits **5-HT$_{2A}$receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor**, and **Histamine H1 receptor**, with **K$_i$** values of 5.6, 10, 0.765/0.13, 3.4, and 8 nM, respectively.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Perphenazine D8 Dihydrochloride

Cat. No.: HY-A0077AS

Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-04995274

Cat. No.: HY-18137

PF-04995274 is a potent, high-affinity, orally active and partial **serotonin 4 receptor (5-HT$_4$R)** agonist.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Phenylbiguanide

(N-Phenylbiguanide; PBG; 1-Phenylbiguanide)

Cat. No.: HY-101331

Phenylbiguanide is a **5-HT$_3$ receptor** selective agonist with an **EC$_{50}$** of 3.0±0.1 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Piboserod

(SB-207266)

Cat. No.: HY-15574

Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist. IC50 value: Target: 5-HT4 antagonist in vitro: Piboserod did not modify the basal contractions but concentration-dependently antagonized the ability of 5-HT to enhance bladder strip contractions to EFS.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Piboserod hydrochloride

(SB-207266 hydrochloride)

Cat. No.: HY-15574A

Piboserod (SB 207266) Hcl is a selective 5-HT(4) receptor antagonist. IC50 value: Target: 5-HT4 antagonist in vitro: Piboserod did not modify the basal contractions but concentration-dependently antagonized the ability of 5-HT to enhance bladder strip contractions to EFS.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Pimavanserin

(ACP-103)

Cat. No.: HY-14557

Pimavanserin is a selective inverse agonist of the **5-HT2A** receptor with **pIC$_{50}$** and **pK$_d$** of 8.73 and 9.3, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Pimavanserin hemitartrate

(ACP-103 hemitartrate)

Cat. No.: HY-14557A

Pimavanserin (ACP-103) hemitartrate is a potent **5-HT 2A** receptor inverse agonist with **pIC$_{50}$** and **pK$_i$** of 8.73 and 9.3, respectively.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Pimavanserin-d9

(ACP-103-d9)

Cat. No.: HY-14557S

Pimavanserin-d9 (ACP-103-d9) is the deuterium labeled Pimavanserin. Pimavanserin is a selective inverse agonist of the **5-HT2A** receptor with **pIC$_{50}$** and **pK$_d$** of 8.73 and 9.3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pimethixene

(Pimetixene)

Cat. No.: HY-B1101

Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pimethixene maleate

(Pimetixene maleate)

Cat. No.: HY-B1101A

Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Pindolol

(LB-46)

Cat. No.: HY-B0982

Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33nM).



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Pindolol-d7

Cat. No.: HY-B0982S

Pindolol-d7 (LB-46-d7) is the deuterium labeled Pindolol. Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (K_i=33 nM).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg, 25 mg

Pipamperone

(Floropipamide; McN-JR 3345; R 3345)

Cat. No.: HY-100703

Pipamperone (Floropipamide; McN-JR 3345; R 3345) is a high-affinity antagonist of **5-HT$_{2A}$ receptor** (**pK$_i$**=8.2) and **D$_4$ receptor** (**pK$_i$**=8.0) and a low-affinity antagonist of D$_2$ receptor (pK$_i$=6.7).



Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg

Pirenperone

(R 47465)

Cat. No.: HY-B1737

Pirenperone (R 47465) is a **5-HT$_2$ serotonin receptor** antagonist. Pirenperone exhibits modest anxiolytic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piromelatine

(Neu-P11)

Cat. No.: HY-105285

Piromelatine (Neu-P11) is a **melatonin MT$_1$/MT$_2$** receptor agonist, **serotonin 5-HT$_{1A}$/5-HT$_{1D}$** agonist, and **serotonin 5-HT$_{2B}$** antagonist.



Purity: 99.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pizotifen

(Pizotyline; BC-105)

Cat. No.: HY-B0115

Pizotifen (Pizotyline) is a potent **5-HT$_2$** receptor antagonist, with a high affinity for **5-HT$_{1C}$** binding site.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Pizotifen malate

(Pizotyline malate; BC-105 malate)

Cat. No.: HY-B0115A

Pizotifen malate (Pizotyline malate) is a potent **5-HT$_2$** receptor antagonist, with a high affinity for **5-HT$_{1C}$** binding site.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

PNU-142633

Cat. No.: HY-103131

PNU-142633 is a high affinity, selective and orally active **5-HT$_{1D}$ receptor** agonist with **K$_i$**s of 6 nM and > 18 000 nM for human **5-HT$_{1D}$ receptor** and human 5-HT$_{1B}$ receptor, respectively. PNU-142633 has anti-migraine efficacy.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

PNU-282987 free base

Cat. No.: HY-12560

PNU-282987 (free base) (Compound C7) is a potent **α7 nicotinic acetylcholine receptor (nAChR)** agonist with an **EC$_{50}$** of 154 nM. PNU-282987 (free base) is also a functional antagonist of the **5-HT$_3$ receptor** with an **IC$_{50}$** of 4541 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PNU-96415E

Cat. No.: HY-103404

PNU-96415E is a selective **D$_4$/5-HT$_{2A}$** antagonist. PNU-96415E may have potential antipsychotic efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prucalopride

Cat. No.: HY-14151

Prucalopride (R093877) is a drug acting as a selective, high affinity 5-HT4 receptor agonist(pKi=8.6/8.1 for 5-HT4a/4b); >150-fold higher affinity for 5-HT4 receptors than for other receptors.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Prucalopride succinate

(R-108512)

Cat. No.: HY-12694

Prucalopride succinate is a selective, high affinity 5-HT4 receptor agonist with pKi of 8.6/8.1 for 5-HT4a/4b.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Prucalopride-13C,d3

Cat. No.: HY-14151S

Prucalopride-13C,d3 is the 13C- and deuterium labeled.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRX-07034 hydrochloride

Cat. No.: HY-14559

PRX-07034 hydrochloride is a highly selective and potent **5-HT6 receptor** antagonist with a K_i= 4-8 nM and an **IC_{50}** of 19 nM. PRX-07034 can be used for the research of enhancing working memory and cognitive flexibility.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PRX-08066

Cat. No.: HY-15472

PRX-08066 is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist that causes selective vasodilation of pulmonary arteries.



Purity: 97.62%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

PRX933 hydrochloride

(GW876167 hydrochloride; BVT-933 hydrochloride)

Cat. No.: HY-100171

PRX933 hydrochloride is a **5-HT_{2c} receptor** agonist extracted from patent WO 2014140631 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PU02

Cat. No.: HY-103118

PU02, a derivative of 6-MP (HY-13677), is a negative allosteric modulator (NAM) of **5-HT_3 receptor**, with **IC_{50}** values of 0.36 and 0.73 μM in HEK293 cells transfected with human 5-HT_3A and 5-HT_3AB receptors respectively.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Puerarin

Cat. No.: HY-N0145

Puerarin, an isoflavone extracted from Radix puerariae, is a **5-HT2C** receptor antagonist.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pumosetrag Hydrochloride

(MKC-733; DDP-733)

Cat. No.: HY-19650

Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available **5-HT3** partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.



Purity: 99.77%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Quetiapine

(ICI204636)

Cat. No.: HY-14544

Quetiapine (ICI204636) is a **5-HT receptors** agonist with a **pEC_{50}** of 4.77 for human 5-HT1A receptor. Quetiapine is a **dopamine receptor** antagonist with a **pIC_{50}** of 6.33 for human D2 receptor.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Quetiapine hemifumarate

Cat. No.: HY-B0031

Quetiapine hemifumarate is a **5-HT receptors** agonist with a **pEC_{50}** of 4.77 for human **5-HT1A receptor**. Quetiapine hemifumarate is a **dopamine receptor** antagonist with a **pIC_{50}** of 6.33 for human **D2 receptor**.



Purity: 98.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Quetiapine-d4 fumarate

Cat. No.: HY-B0031S

Quetiapine D4 fumarate is the deuterium labeled Quetiapine fumarate. Quetiapine fumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Quetiapine-d4 hemifumarate

Cat. No.: HY-B0031S1

Quetiapine D4 hemifumarate is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Quetiapine-d8 fumarate

Cat. No.: HY-B0031S2

Quetiapine-d8 fumarate is the deuterium labeled Quetiapine. Quetiapine is a **5-HT receptors** agonist with a **pEC_{50}** of 4.77 for human **5-HT1A receptor**. Quetiapine is a **dopamine receptor** antagonist with a **pIC_{50}** of 6.33 for human **D2 receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quetiapine-d8 hemifumarate

Cat. No.: HY-B0031S3

Quetiapine-d8 hemifumarate is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a **5-HT receptors** agonist with a **pEC_{50}** of 4.77 for human **5-HT1A receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R 59-022

(DKGI-I; Diacylglycerol kinase inhibitor I)

Cat. No.: HY-107613

R 59-022 (DKGI-I) is a **diacylglycerol kinase** inhibitor (**IC_{50}**=2.8 μM). R 59-022 is a **5-HTR** antagonist, and activates **protein kinase C (PKC)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

R 59-022-d5

(DKGI-I-d5; Diacylglycerol kinase inhibitor I-d5)

Cat. No.: HY-107613S

R 59-022-d5 (DKGI-I-d5) is the deuterium labeled R 59-022. R 59-022 (DKGI-I) is a **diacylglycerol kinase** inhibitor (**IC_{50}**=2.8 μM). R 59-022 is a **5-HTR** antagonist, and activates **protein kinase C (PKC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ramosetron Hydrochloride

(YM060)

Cat. No.: HY-B0595

Ramosetron Hydrochloride(YM060 Hydrochloride) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. Target: 5-HT3 Receptor Ramosetron hydrochloride selectively blocks serotonin receptors (5-HT3).



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Relenopride hydrochloride

(YKP10811 hydrochloride)

Cat. No.: HY-16729A

Relenopride (YKP10811) hydrochloride is a specific and selective **5-HT_4 receptor** agonist (K_i=4.96 nM). Relenopride hydrochloride has 120-fold and 6-fold lower affinity, respectively, for 5-HT_{2A} (K_i=600 nM) and 5-HT_{2B} receptors (K_i=31 nM) than for 5-HT_4.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Renzapride

(BRL 24924)

Cat. No.: HY-14147

Renzapride (BRL 24924), a substituted benzamide, is a full **5-HT_4 receptor** agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a **5HT2b** and **5HT3 receptor** antagonist. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Repinotan

(BAY x 3702 free base)

Cat. No.: HY-12959

Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active **5-HT1A receptor** agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Revexepride

Cat. No.: HY-U00373

Revexepride is a highly selective **5-HT4 receptor** agonist, and a potential inducer of **CYP3A4 enzyme**, used for the treatment of gastroesophageal reflux disease.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RG-12915

Cat. No.: HY-19110

RG-12915 is a selective **5-HT3** antagonist, with IC_{50} value of 0.16 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Risperidone

(R 64 766)

Cat. No.: HY-11018

Risperidone is a serotonin **5-HT$_2$ receptor** blocker, **P-Glycoprotein** inhibitor and potent **dopamine D$_2$ receptor** antagonist, with K_is of 4.8, 5.9 nM for 5-HT$_{2A}$ and dopamine D$_2$ receptor, respectively.



Purity: 98.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Risperidone hydrochloride

(R 64 766 hydrochloride)

Cat. No.: HY-11018A

Risperidone hydrochloride (R 64 766 hydrochloride) **5-HT$_2$ receptor** blocker, **P-Glycoprotein** inhibitor and potent **dopamine D$_2$ receptor** antagonist, with K_is of 4.8, 5.9 nM for 5-HT$_{2A}$ and dopamine D$_2$ receptor, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Risperidone mesylate

(R 64 766 mesylate)

Cat. No.: HY-11018B

Risperidone mesylate(R 64 766 mesylate) is a serotonin **5-HT$_2$ receptor** blocker, **P-Glycoprotein** inhibitor and potent **dopamine D$_2$ receptor** antagonist, with K_is of 4.8, 5.9 nM for 5-HT$_{2A}$ and dopamine D$_2$ receptor, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Risperidone-d4

(R 64 766-d4)

Cat. No.: HY-110232

Risperidone-d4 (R 64 766-d4) is the deuterium labeled Risperidone. Risperidone is a serotonin **5-HT$_2$ receptor** blocker, **P-Glycoprotein** inhibitor and potent **dopamine D$_2$ receptor** antagonist, with K_is of 4.8, 5.9 nM for 5-HT$_{2A}$ and dopamine D$_2$ receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 5 mg

Ritanserin

(R 55667)

Cat. No.: HY-10791

Ritanserin (R 55667) is a highly potent, relatively selective, orally active, long acting antagonist of **5-HT$_2$ receptor**, with an IC_{50} of 0.9 nM, less active on Histamine H$_1$, Dopamine D$_2$, Adrenergic α_1, Adrenergic α_2 receptors.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg

Rizatriptan benzoate

(MK 462)

Cat. No.: HY-B0206

Rizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches. Target: 5-HT1 agonist Rizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Rizatriptan-d6 benzoate

Cat. No.: HY-B0206S

Rizatriptan-d6 benzoate (MK 462-d6) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Ro 04-6790

Cat. No.: HY-14335

Ro 04-6790 is a potent, competitive and selective **5-HT$_6$** receptor antagonist with **pK$_i$** values of 7.26, 7.35 for rat and human 5-HT6 receptors, respectively. Ro 04-6790 has no affinity at other receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro60-0175

Cat. No.: HY-123838

Ro60-0175 is a potent and selective agonist of **5-HT$_{2C}$** receptor. Ro60-0175 reduces cocaine self-administration, and the ability of cocaine to reinstate responding after extinction of drug-seeking behavior.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro60-0175 fumarate

Cat. No.: HY-103140

Ro60-0175 fumarate is a potent and selective agonist of **5-HT$_{2C}$** receptor. Ro60-0175 fumarate reduces Cocaine self-administration, and the ability of Cocaine to reinstate responding after extinction of drug-seeking behavior.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Rodatristat

(KAR5417)

Cat. No.: HY-120083

Rodatristat (KAR5417) is a potent **tryptophan hydroxylase 1 (TPH1)** and **TPH2** inhibitor with **IC$_{50}$**s value of 33 nM and 7 nM, respectively, and shows robust reduction of **intestinal serotonin (5-HT)** levels in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rodatristat ethyl

(KAR5585)

Cat. No.: HY-101124

Rodatristat ethyl (KAR5585) is a first-in-class oral **tryptophan hydroxylase 1 (TPH1)** Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of **5-HT** and significantly reduces pulmonary arterial hypertension (PAH).



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Roluperidone

(CYR-101; MIN-101; MT-210)

Cat. No.: HY-19469

Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for **5-HT$_{2A}$** and **sigma-2** receptors (**K$_i$** of 7.53 nM and 8.19 nM for 5-HT$_{2A}$ and sigma-2, respectively).



Purity: 99.51%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rotigotine

(N-0437; N-0923)

Cat. No.: HY-75502

Rotigotine (N-0437; N-0923) is a full agonist of **dopamine receptor**, a partial agonist of the **5-HT1A receptor**, and an antagonist of the **α2B-adrenergic receptor**, with **K$_i$**s of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine...



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Rotigotine Hydrochloride

(N-0923 Hydrochloride)

Cat. No.: HY-A0007

Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of **dopamine receptor**, a partial agonist of the **5-HT1A receptor**, and an antagonist of the **α2B-adrenergic receptor**, with **K$_i$** of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine...



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Rotundine

((-)-Tetrahydropalmatine; L-Tetrahydropalmatine)

Cat. No.: HY-N0096

Rotundine is an antagonist of **dopamine D1**, **D2** and **D3 receptors** with **IC$_{50}$**s of 166 nM, 1.4 μM and 3.3 μM, respectively. Rotundine is also an antagonist of **5-HT$_{1A}$** with an **IC$_{50}$** of 370 nM.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

RS 39604

Cat. No.: HY-101343

RS 39604 is a potent, selective, and orally active **5-HT$_4$ receptor** antagonist with a **pK$_i$** of 9.1 in guinea pig striatal membranes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

RS 67333 hydrochloride

Cat. No.: HY-101341

RS 67333 hydrochloride is a potent and selective **5-HT4 receptor (5-HT4R)** partial agonist with a **pK_i** of 8.7 in guinea-pig striatum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RS-127445

Cat. No.: HY-15419A

RS-127445 is a selective, high affinity, orally bioavailable **5-HT_{2B} receptor** antagonist with a **pK_i** of 9.5. RS-127445 shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RS-127445 hydrochloride

Cat. No.: HY-15419

RS-127445 hydrochloride is a selective, high affinity, orally bioavailable **5-HT_{2B} receptor** antagonist with a **pK_i** of 9.5. RS-127445 hydrochloride shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RU 24969

Cat. No.: HY-16688

RU 24969 is a preferential **5-HT_{1B}** agonist, with a **K_i** of 0.38 nM, but also displays appreciable affinity for the **5-HT_{1A} receptor** (K_i=2.5 nM), and has low affinity for other receptor sites in the brain. RU 24969 could decrease fluid consumption and increase forward locomotion.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RU 24969 hemisuccinate

Cat. No.: HY-16688B

RU 24969 hemisuccinate is a preferential **5-HT_{1B}** agonist, with a **K_i** of 0.38 nM, but also displays appreciable affinity for the **5-HT_{1A} receptor** (K_i=2.5 nM), and has low affinity for other receptor sites in the brain.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sarizotan

(EMD 128130)

Cat. No.: HY-100820

Sarizotan (EMD 128130) is an orally active serotonin **5-HT_{1A} receptor** and **dopamine receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sarpogrelate hydrochloride

(MCI-9042)

Cat. No.: HY-10564

Sarpogrelate hydrochloride (MCI-9042) is a selective **5-HT_2R** antagonist, with **pK_i**s of 8.52, 6.57, and 7.43 for 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sarpogrelate-d3 hydrochloride

(MCI-9042-d3)

Cat. No.: HY-10564S

Sarpogrelate-d3 hydrochloride (MCI-9042-d3) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective **5-HT_2R** antagonist, with **pK_i**s of 8.52, 6.57, and 7.43 for 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB 204741

Cat. No.: HY-103153

SB 204741 is a selective and high affinity **5-HT_{2B}** antagonist with a **pK_i** value of 7.1.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SB 206553 hydrochloride

Cat. No.: HY-103135

SB 206553 hydrochloride is a high affinity, selective and orally active **5-HT_{2B} / 5-HT_{2C} receptor** antagonist (rat 5-HT_{2B} pA2 = 8.89, human 5-HT_{2C} pKi = 7.92). SB 206553 possesses anxiolytic-like properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB 242084

Cat. No.: HY-13409

SB 242084 is a 5-HT2C receptor antagonist(pKi=9.0) that displays 158- and 100-fold selectivity over 5-HT2A and 5-HT2B receptors respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SB 242084 dihydrochloride

Cat. No.: HY-13409A

SB 242084 hydrochloride is a 5-HT2C receptor antagonist(pKi=9.0) that displays 158- and 100-fold selectivity over 5-HT2A and 5-HT2B receptors respectively.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SB 243213

Cat. No.: HY-103112B

SB 243213 is an orally active, selective and high-affinity **5-HT$_{2C}$ receptor** antagonist with a **pK$_i$** of 9.37 and a **pK$_b$** of 9.8 for human 5-HT$_{2C}$ receptor. SB 243213 shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB 243213 dihydrochloride

Cat. No.: HY-103112A

SB 243213 dihydrochloride is an orally active, selective and high-affinity **5-HT$_{2C}$ receptor** antagonist with a **pK$_i$** of 9.37 and a **pK$_b$** of 9.8 for human 5-HT$_{2C}$ receptor.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB 243213 hydrochloride

Cat. No.: HY-103112

SB 243213 hydrochloride is an orally active, selective and high-affinity **5-HT$_{2C}$ receptor** antagonist with a **pK$_i$** of 9.37 and a **pK$_b$** of 9.8 for human 5-HT$_{2C}$ receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB 258719

Cat. No.: HY-U00443

SB 258719 is a selective **5-HT$_7$** receptor antagonist with high affinity (**pK$_i$**=7.5) for the receptor. SB 258719 can be used for the research of cancer and neurological disease.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SB 258719 hydrochloride

Cat. No.: HY-103123

SB 258719 hydrochloride is a selective **5-HT$_7$** receptor antagonist displayed high affnity (**pK$_i$**=7.5) for the receptor. SB-258719 hydrochloride can be used for the research of cancer and neurological diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB 271046 Hydrochloride

(SB 271046A)

Cat. No.: HY-14336A

SB 271046 Hydrochloride (SB 271046A) is a potent, selective and orally active **5-HT6 receptor** antagonist with **pK$_i$** of 9.02, 8.55, and 8.81 for rat, pig and human, respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SB-200646

Cat. No.: HY-103129A

SB-200646 is the first selective **5-HT$_{2B/2C}$** over 5-HT$_{2A}$ receptor antagonist with **pK$_i$** values of 7.5, 6.9 and 5.2 for **5-HT$_{2B}$**, **5-HT$_{2C}$** and 5-HT$_{2A}$, respectively. SB-200646 is orally active and has electrophysiological and anxiolytic properties in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-200646A

Cat. No.: HY-103129

SB-200646A is the first selective **5-HT$_{2B/2C}$** over 5-HT$_{2A}$ receptor antagonist with **pK$_i$** values of 7.5, 6.9 and 5.2 for **5-HT$_{2B}$**, **5-HT$_{2C}$** and 5-HT$_{2A}$, respectively. SB-200646A is orally active and has electrophysiological and anxiolytic properties in vivo.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB-203186 hydrochloride

Cat. No.: HY-101222

SB-203186 hydrochloride is a potent, selective and competitive **5-HT$_4$** antagonist.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-215505

Cat. No.: HY-18596

SB-215505 is a potent and subtype-selective **5-HT$_{2B}$** receptor antagonist with **pK$_i$** values of 8.3, 6.77, 7.66 for 5-HT$_{2B}$, 5-HT$_{2A}$, 5-HT$_{2C}$, respectively. SB-215505 increases wakefulness and motor activity in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-221284

Cat. No.: HY-103155

SB 221284 is a selective **5-HT$_{2C/2B}$** receptor antagonist with **pK$_i$** values are 6.4, 7.9 and 8.6 for **5-HT$_{2A}$**, **5-HT$_{2B}$** and **5-HT$_{2C}$** receptors, respectively. SB 221284 can be used for the research of neurological disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-224289 hydrochloride

(SB-224289A)

Cat. No.: HY-101105A

SB-224289 hydrochloride is a selective **5-HT1B receptor** antagonist, with anxiolytic effect.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SB-269970

Cat. No.: HY-15370

SB-269970 is a potent, selective and brain-penetrant **5-HT7 receptor** antagonist with a **pK$_i$** of 8.3. SB-269970 exhibits >50-fold selectivity against other 5-HT receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-269970 hydrochloride

(SB-269970A)

Cat. No.: HY-15370A

SB-269970 hydrochloride is a potent, selective and brain-penetrant **5-HT7 receptor** antagonist with a **pK$_i$** of 8.3. SB-269970 hydrochloride exhibits >50-fold selectivity against other 5-HT receptors.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SB-277011 hydrochloride

(SB-277011A hydrochloride)

Cat. No.: HY-10847B

SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally bioavailable and brain penetrate **dopamine D$_3$ receptor (D$_3$R)** antagonist with **K$_i$** values of 10.7 nM and 11.2 nM at rodent and human D$_3$R, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-399885 hydrochloride

Cat. No.: HY-103099

SB-399885 hydrochloride is a **5-HT$_6$ receptor** antagonist.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-616234-A

Cat. No.: HY-19477

SB-616234-A is a selective and orally bioavailable **5-HT1B receptor** antagonist, with anxiolytic and antidepressant activity.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB228357

Cat. No.: HY-103154

SB228357 is a selective, potent and orall active **5-HT$_{2C/2B}$ receptor** antagonist with **pK$_i$** values of 6.9, 8.0 and 9.0 for **5-HT$_{2A}$**, **5-HT$_{2B}$** and **5-HT$_{2C}$**, respectively. SB228357 has antidepressant/anxiolytic effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SCH 39166 hydrobromide

(SCH391660)

Cat. No.: HY-110033

SCH 39166 hydrobromide (SCH391660) is potent and selective antagonist of **dopamine D1/D5 receptor**, with K_is of 1.2 nM and 2.0 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SCH-23390 hydrochloride

(R-(+)-SCH-23390 hydrochloride)

Cat. No.: HY-19545A

SCH-23390 hydrochloride (R-(+)-SCH-23390 hydrochloride) is a potent and selective **dopamine D_1-like receptor** antagonist with K_is of 0.2 nM and 0.3 nM for the D_1 and D_5 **receptor**, respectively.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SCH-23390 maleate

(R-(+)-SCH-23390 maleate)

Cat. No.: HY-108400

SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective **dopamine D_1-like receptor** antagonist with K_is of 0.2 nM and 0.3 nM for the D_1 and D_5 **receptor**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SCH-23390-d3 hydrochloride

Cat. No.: HY-19545AS

SCH-23390-d3 (R-(+)-SCH-23390-d3) hydrochloride is the deuterium labeled SCH-23390 hydrochloride.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

SEP-363856

(SEP-856)

Cat. No.: HY-136109A

SEP-363856 (SEP-856), an orally active and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 (SEP-856) has the potential for the study of schizophrenia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SEP-363856 hydrochloride

(SEP-856 hydrochloride)

Cat. No.: HY-136109

SEP-363856 hydrochloride (SEP-856 hydrochloride), an orally active and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 hydrochloride (SEP-856 hydrochloride) has the potential for the study of schizophrenia.



Purity: 99.78%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sertindole

(Lu 23-174)

Cat. No.: HY-14543

Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Target: Multi-target In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Sertindole-d4

Cat. No.: HY-14543S

Sertindole-d4 (Lu 23-174-d4) is the deuterium labeled Sertindole. Sertindole, a neuroleptic, is one of the newer antipsychotic medications available.



Purity: >98%
Clinical Data:
Size: 1 mg

Setiptiline

(Org-8282)

Cat. No.: HY-32329

Setiptiline (Org-8282) is a **serotonin receptor** antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).



Purity: 96.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Setiptiline maleate

(MO-8282)

Cat. No.: HY-32329A

Setiptiline maleate (MO-8282 maleate) is a **serotonin receptor** antagonist. Setiptiline maleate is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).



Purity: 98.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Setiptiline-d3

Cat. No.: HY-32329S

Setiptiline-d3 (Org-8282-d3) is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a **serotonin receptor** antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

SGS518 oxalate

Cat. No.: HY-19668A

SGS518 oxalate is a selective **5-HT$_6$R** antagonist. SGS518 oxalate can be used for the research of cognitive impairments such as amnesia, anxiety and depression, and it is effective in protecting mouse retina at high doses[</sup>].



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SKF-83566

Cat. No.: HY-103430A

SKF-83566 is a potent, blood-brain permeable and orally active **D1-like dopamine receptor (D1DR)** antagonist and a weaker competitive antagonist at the vascular 5-HT$_2$ receptor (K_i=11 nM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SKF-83566 hydrobromide

Cat. No.: HY-103430

SKF-83566 hydrobromide is a potent, blood-brain permeable and orally active **D1-like dopamine receptor (D1DR)** antagonist and a weaker competitive antagonist at the vascular 5-HT$_2$ receptor (K_i=11 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Spiperone

(Siroperidol)

Cat. No.: HY-B1371

Spiperone is a potent **dopamine D2, serotonin 5-HT$_{1A}$, and serotonin 5-HT$_{2A}$ antagonist. Spiperone is a widely used pharmacological tool. Spiperone has the potential for the research of neurology diseases.**.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Spiperone hydrochloride

(Siroperidol hydrochloride)

Cat. No.: HY-B1371A

Spiperone hydrochloride (Siroperidol hydrochloride) is a selective **dopamine D$_2$ receptor** (K_i values of 0.06 nM, 0.6 nM, 0.08 nM, ~350 nM, ~3500 nM for **D$_2$**, D$_3$, D$_4$, D$_1$ and D$_5$ receptors, respectively) and **5-HT$_{2A}$/5-HT$_{1A}$ receptor** (K_is of 1 nM/49 nM)...



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mg

Spiramide

(AMI-193)

Cat. No.: HY-100971

Spiramide (AMI-193) is a potent and selective antagonist of **5-HT$_2$** and **dopamine D2 receptor**, with K_is of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT$_2$ versus **5-HT$_{1C}$** (K_i=4300 nM) receptors.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR 57227A

Cat. No.: HY-102064

SR 57227A is a potent, orally active and selective **5-HT3 receptor** agonist, with ability to cross the blood brain barrier.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ST1936

Cat. No.: HY-103110

ST1936 is a selective, nanomolar affinity **5-HT$_6$ receptor** agonist with K_i values of 13 nM, 168 nM and 245 nM for human **5-HT$_6$**, 5-HT$_7$ and 5-HT$_{2B}$ receptors, respectively. ST1936 also shows moderate affinity (K_i of 300 nM) for human and rat **α2 adrenergic receptor**.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ST1936 oxalate

Cat. No.: HY-103110A

ST1936 oxalate is a selective, nanomolar affinity **5-HT$_6$ receptor** agonist with K_i values of 13 nM, 168 nM and 245 nM for human **5-HT$_6$**, 5-HT$_7$ and 5-HT$_{2B}$ receptors, respectively. ST1936 oxalate also shows moderate affinity (K_i of 300 nM) for human and rat **α2 adrenergic receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Strictosidinic acid

Cat. No.: HY-N7514

Strictosidinic acid, an orally active glycoside indole monoterpene alkaloid isolated from Psychotria myriantha leaves, inhibits precursor enzymes of **5-HT** biosynthesis and reduces the 5-HT levels. Strictosidinic acid has peripheral analgesic and antipyretic activities in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Sulamserod

(RS-100302)

Cat. No.: HY-101668

Sulamserod is a **5-HT4 receptor** antagonist, with antiarrhythmic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sumatriptan

(GR 43175 free base)

Cat. No.: HY-B0121B

Sumatriptan (GR 43175 free base) is an orally active **5-HT1 receptor** agonist with K_is of 17 nM, 27 nM and 100 nM for **5-HT1D**, **5-HT1B** and **5-HT1A receptors**, respectively. Sumatriptan can be used for migraine headache research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sumatriptan succinate

(GR 43175)

Cat. No.: HY-B0121

Sumatriptan succinate (GR 43175) is an orally active **5-HT1 receptor** agonist with K_is of 17 nM, 27 nM and 100 nM for **5-HT1D**, **5-HT1B** and **5-HT1A receptors**, respectively. Sumatriptan succinate can be used for migraine headache research.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sumatriptan-d6

Cat. No.: HY-B0121BS1



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Sumatriptan-d6 succinate

Cat. No.: HY-B0121BS



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Syk Inhibitor II

Cat. No.: HY-112390A

Syk Inhibitor II is a potent, high selective and ATP-competitive **Syk** inhibitor with an IC_{50} of 41 nM. Syk Inhibitor II inhibits **5-HT** release from RBL-cells with an IC_{50} of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

T 82

Cat. No.: HY-U00028

T 82 is a potent **5-HT3** antagonist and **acetylcholinesterase (AChE)** inhibitor, used for treatment of Alzheimer's Disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Talipexole dihydrochloride

(B-HT 920 dihydrochloride)

Cat. No.: HY-A0008

Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tandospirone

(SM-3997)

Cat. No.: HY-14558

Tandospirone (SM-3997) is a potent and selective **5-HT_{1A}** receptor partial agonist, with a K_i of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tandospirone citrate

(SM-3997 citrate)

Cat. No.: HY-B0061

Tandospirone citrate is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over SR-2, SR-1C, α1, α2, D1 and D2 receptors (Ki values ranging from 1300-41000 nM).



Purity: 98.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Tedatioxetine hydrobromide

(Lu AA24530 hydrobromide)

Cat. No.: HY-101755

Tedatioxetine (Lu AA24530) hydrobromide acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and **5-HT$_{2A}$**, **5-HT$_{2C}$**, **5-HT$_3$** and **α$_{1A}$-adrenergic receptor** antagonist
. ,.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tegaserod

Cat. No.: HY-14153

Tegaserod is a **serotonin receptor 4** agonist (**HTR4**) used in the treatment of irritable bowel syndrome (IBS). Anti-tumor activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tegaserod maleate

(SDZ-HTF-919; HTF-919)

Cat. No.: HY-14153A

Tegaserod maleate is a selective **5-HT$_4$** receptor partial agonist and a **5-HT$_{2B}$** receptor antagonist. Tegaserod maleate exhibits a promotile effect throughout the gastrointestinal (GI) tract.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tegaserod-13C,d3 maleate

(SDZ-HTF-919-13C,d3; HTF-919-13C,d3)

Cat. No.: HY-14153AS

Tegaserod-13C,d3 (maleate) is the 13C- and deuterium labeled. Tegaserod maleate is a selective 5-HT4 receptor partial agonist and a 5-HT2B receptor antagonist. Tegaserod maleate exhibits a promotile effect throughout the gastrointestinal (GI) tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Temanogrel

(APD791)

Cat. No.: HY-10560

Temanogrel is a highly selective **5-HT$_{2A}$ receptor** antagonist with a **K$_i$** of 4.9 nM.



Purity: 98.94%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tertatolol

((±)-Tertatolol; Racemic Tertatolol; dl-Tertatolol)

Cat. No.: HY-U00356

Tertatolol is a potent antagonist of **beta-adrenoceptor** and **5-HT receptor**, with unique renal vasodilatatory effects.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

TG6-10-1

Cat. No.: HY-16978

TG6-10-1 is an **EP2** antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Thioridazine

Cat. No.: HY-B0965A

Thioridazine, an antagonist of the **dopamine receptor D2** family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of **PI3K-Akt-mTOR** signaling pathways with anti-angiogenic effect.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Thioridazine hydrochloride

Cat. No.: HY-B0965

Thioridazine hydrochloride, an orally active antagonist of the **dopamine receptor D2** family proteins, exhibits potent anti-psychotic and anti-anxiety activities.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Thioridazine-d3 2-Sulfone

Cat. No.: HY-B0965S

Thioridazine-d3 2-Sulfone is the deuterium labeled Thioridazine hydrochloride. Thioridazine hydrochloride, an orally active antagonist of the **dopamine receptor D2** family proteins, exhibits potent anti-psychotic and anti-anxiety activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Thioridazine-d3 hydrochloride

Cat. No.: HY-B0965AS

Thioridazine-d3 hydrochloride is the deuterium labeled Thioridazine. Thioridazine, an antagonist of the **dopamine receptor D2** family proteins, exhibits potent anti-psychotic and anti-anxiety activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Tianeptine

Cat. No.: HY-90003

Tianeptine is a selective facilitator of **5-HT** uptake. Tianeptine has no affinity for a wide range of receptors, including 5-HT and dopamine (IC_{50}>10 μM) and has no effect on noradrenalin or dopamine uptake.



Purity: 99.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tianeptine sodium salt

Cat. No.: HY-90003A

Tianeptine sodium salt is a selective facilitator of **5-HT** uptake. Tianeptine sodium salt has no affinity for a wide range of receptors, including 5-HT and dopamine (IC_{50}>10 μM) and has no effect on noradrenalin or dopamine uptake.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TIK-301

(PD-6735; LY-156735)

Cat. No.: HY-106136

TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active **melatonin MT_1** and **MT_2 receptors** agonist with K_is of 0.081 nM and 0.042 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trazodone hydrochloride

(AF-1161)

Cat. No.: HY-B0478

Trazodone (hydrochloride) (AF-1161) is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Trimipramine maleate

Cat. No.: HY-B1213

Trimipramine maleate is a 5-HT receptor antagonist, with pK_is of 6.39, 8.10, 4.66 for 5-HT_{1C}, 5-HT_2 and 5-HT_{1A}, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Trimipramine-d3 maleate

Cat. No.: HY-B1213S

Trimipramine-d3 maleate is the deuterium labeled Trimipramine maleate. Trimipramine maleate is a 5-HT receptor antagonist, with pK_is of 6.39, 8.10, 4.66 for 5-HT_{1C}, 5-HT_2 and 5-HT_{1A}, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Tropisetron

(SDZ-ICS-930 free base)

Cat. No.: HY-B0072

Tropisetron (SDZ-ICS-930 free base) is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Tropisetron Hydrochloride

(SDZ-ICS-930)

Cat. No.: HY-B0020

Tropisetron Hydrochloride (SDZ-ICS-930) is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

U92016A hydrochloride

Cat. No.: HY-117507

U92016A hydrochloride is a potent, metabolically stable, orally acitive **5-HT1A** receptor agonist with an exceptionally high degree of intrinsic activity. U92016A hydrochloride binds with high affinity to human 5-HT1A receptors expressed in Chinese hamster ovary cells (K_i=0.2 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UCSF648

Cat. No.: HY-145700

UCSF648 (Compound 5A6-48) is a chemical probe for the **5-HT_{5A} serotonin receptor**. UCSF648 weakly activates **ADRA2A** and **MTNR1A**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UCSF678

Cat. No.: HY-145698

UCSF678 is a 42 nM arrestin-biased partial agonist at the 5-HT_{5A}R with a more restricted off-target profile and decreased assay liabilities. UCSF678 is a selective probe with which to study the function of the 5-HT_{5A}R.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UCSF686

Cat. No.: HY-145699

UCSF686 is a probe with which to study the function of the 5-HT_{5A}R. UCSF686 loses affinity at 5-HT_{5A}R (>10000 nM) but not at 5-HT_{1A}R, 5-HT_{2B}R, and 5-HT_7R. UCSF686 controls for off-target effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC9994

Cat. No.: HY-117829

UNC9994, an analog of Aripiprazole, is a functionally selective β-arrestin-biased dopamine D2 receptor (D2R) agonist with **EC_{50}** <10 nM for β-arrestin-2 recruitment to D2 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urapidil

Cat. No.: HY-B0716

Urapidil is an **α1 adrenoreceptor** antagonist and a **5-HT_{1A} receptor** agonist.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Urapidil D6

Cat. No.: HY-B0716S

Urapidil D6 is a deuterium labeled Urapidil. Urapidil is an **α1-adrenoreceptor** antagonist and a **5-HT_{1A} receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urapidil hydrochloride

Cat. No.: HY-B0354A

Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist.



Purity: 98.95%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Urapidil-d3

Cat. No.: HY-B0716S1

Urapidil-d3 is the deuterium labeled Urapidil. Urapidil is an **α1 adrenoreceptor** antagonist and a **5-HT_{1A} receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urapidil-d4 hydrochloride

Cat. No.: HY-B0354AS

Urapidil-d4 hydrochloride is the deuterium labeled Urapidil hydrochloride. Urapidil hydrochloride is an α1-adrenoceptor antagonist and 5-HT_{1A} receptor agonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Usmarapride

(SUVN-D4010) Cat. No.: HY-116565

Usmarapride (SUVN-D4010) is a potent, selective, orally active and brain penetrant **5-HT$_4$ receptor** partial agonist (**EC$_{50}$**=44 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Usmarapride free base

(SUVN-D4010 free base) Cat. No.: HY-116565A

Usmarapride (SUVN-D4010) free base is a potent, selective, orally active and brain penetrant **5-HT$_4$ receptor** partial agonist (**EC$_{50}$**=44 nM). Usmarapride (SUVN-D4010) free base can be used for the research of cognitive deficits associated with Alzheimer's disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vabicaserin hydrochloride

(SCA 136) Cat. No.: HY-111200

Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (**5-HT$_{2C}$**) **receptor**-selective agonist with an **EC$_{50}$** of 8 nM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Valerenic acid

((-)-Valerenic Acid) Cat. No.: HY-103524

Valerenic acid ((-)-Valerenic Acid), a sesquiterpenoid, is an orally active positive allosteric modulator of **GABA$_A$** receptors. Valerenic acid is also a partial agonist of the **5-HT$_{5a}$ receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Velusetrag

(TD-5108) Cat. No.: HY-10457

Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin **5-HT$_4$ receptor (5-HT4R)**, with a **pK$_i$** of 7.7. Velusetrag exhibits no affinity (K$_i$>10 μM) for 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors.



Purity: 99.64%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg

Velusetrag hydrochloride

(TD-5108 hydrochloride) Cat. No.: HY-10457A

Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin **5-HT$_4$ receptor (5-HT$_4$R)**, with a **pK$_i$** of 7.7. Velusetrag hydrochloride exhibits no affinity (K$_i$>10 μM) for 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors.



Purity: 96.65%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg

Vilazodone

(EMD 68843; SB659746A) Cat. No.: HY-14262

Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active **serotonin reuptake inhibitor (SSRI)** and partial **5-HT$_1$A receptor** agonist.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Vilazodone Hydrochloride

(EMD 68843 Hydrochloride; SB659746A Hydrochloride) Cat. No.: HY-14261

Vilazodone Hydrochloride (EMD 68843 Hydrochloride) is a **serotonin** transporter (SER) inhibitor and **5-HT$_{1A}$** receptor partial agonist.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Vilazodone-d4

(EMD 68843-d4; SB659746A-d4) Cat. No.: HY-14262S

Vilazodone-d4 (EMD 68843-d4) is the deuterium labeled Vilazodone. Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active **serotonin reuptake inhibitor (SSRI)** and partial **5-HT$_1$A receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vilazodone-d8

Cat. No.: HY-14261S

Vilazodone D8 is the a deuterium labeled vilazodone, which is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Volinanserin

(MDL100907; M 100907)

Cat. No.: HY-14940

Volinanserin is a potent and selective antagonist of **5-HT$_2$ receptor**, with a **K$_i$** of 0.36 nM, and shows 300-fold selectivity for 5-HT$_2$ receptor over 5-HT$_{1c}$, alpha-1 and DA D$_2$ receptors. Volinanserin has antipsychotic activity.



Purity: 98.33%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Volinanserin-d4 hydrochloride

Cat. No.: HY-14940S

Volinanserin-d4 (MDL100907-d4) hydrochloride is the deuterium labeled Volinanserin hydrochlorid.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Vortioxetine

(Lu AA 21004)

Cat. No.: HY-15414

Vortioxetine is a inhibitor of **5-HT$_{1A}$**, **5-HT$_{1B}$**, **5-HT$_{3A}$**, **5-HT$_7$** receptor and **SERT**, with **K$_i$** values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Vortioxetine D8

(Lu AA 21004 D8)

Cat. No.: HY-15414S

Vortioxetine D8 is a deuterium labeled Vortioxetine. Vortioxetine is an inhibitor of **5-HT$_{1A}$**, **5-HT$_{1B}$**, **5-HT$_{3A}$**, **5-HT$_7$** receptor and **SERT**, with **K$_i$** values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vortioxetine hydrobromide

(Lu AA21004 hydrobromide)

Cat. No.: HY-15414A

Vortioxetine hydrobromide is a multimodal serotonergic agent, inhibits **5-HT$_{1A}$**, **5-HT$_{1B}$**, **5-HT$_{3A}$**, **5-HT$_7$** receptor and **SERT** with **K$_i$** values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Vortioxetine-d8 hydrobromide

(Lu AA21004-d8 hydrobromide)

Cat. No.: HY-15414AS

Vortioxetine-d8 (Lu AA21004-d8) hydrobromide is the deuterium labeled Vortioxetine hydrobromide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WAY 163909

Cat. No.: HY-15401

WAY 163909 is a potent and selective **5-HT(2C) receptor** agonist with a **K$_i$** of 10.5±1.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WAY-100135 dihydrochloride

Cat. No.: HY-117575A

WAY-100135 dihydrochloride is a selective antagonist at presynaptic and postsynaptic **5-HT$_{1A}$** receptor, with an **IC$_{50}$** of 34 nM at the rat hippocampal 5-HT$_{1A}$ receptor. WAY-100135 dihydrochloride has potential antipsychotic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WAY-100635

Cat. No.: HY-10349

WAY-100635 is a potent and selective 5-HT$_{1A}$ Receptor antagonist with a pIC$_{50}$ of 8.87, an apparent pA$_2$ of 9.71. WAY-100635 is a potent and selective **5-hydroxytryptamine 1A (5-HT1A) receptor** antagonist with an **IC$_{50}$** value of 0.91 nM and **K$_i$** value of 0.39 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WAY-100635 Maleate

Cat. No.: HY-10349A

WAY-100635 maleate is a potent and selective **5-hydroxytryptamine 1A (5-HT1A) receptor** antagonist with an **IC$_{50}$** value of 0.91 nM and **K$_i$** value of 0.39 nM. WAY-100635 maleate has **pIC$_{50}$** values for **5-HT1A** and α1-adrenergic receptors of 8.9 and 6.6, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WAY-181187

(SAX-187)

Cat. No.: HY-14340

WAY-181187 (SAX-187) is a potent and selective full **5-HT6** receptor agonist with a K_i of 2.2 nM and an EC_{50} of 6.6 nM. WAY181187 mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

WAY208466 dihydrochloride

Cat. No.: HY-103133

WAY 208466 dihydrochloride is a potent and selective **5-HT_6 receptor** agonist (EC_{50}=7.3 nM for the human 5-HT_6 receptor). WAY-208466 dihydrochloride elevates cortical GABA levels in rat frontal cortex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Wf-516

Cat. No.: HY-19417A

Wf-516 is an inhibitor of **5-HT reuptake**, and an antagonist of **5-HT1A** and **5-HT2A** receptors, with K_i of 5 nM and 40 nM for 5-HT1A receptor and 5-HT2A receptor in humans, respectively, and has potent antidepressant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Xaliproden hydrochloride

(SR57746A; SR57746 hydrochloride)

Cat. No.: HY-14604

Xaliproden hydrochloride (SR57746A) is a potent, selective and orally active agonist of **5-HT_{1A} receptor**, shows a high affinity for 5-HT_{1A} specific binding sites in the rat hippocampus (IC_{50}=3 nM).



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Xanthotoxol

(8-Hydroxypsoralen)

Cat. No.: HY-30152

Xanthotoxol (8-Hydroxypsoralen) is a biologically active linear furocoumarin, shows strong pharmacological activities as anti-inflammatory, antioxidant, **5-HT** antagonistic, and neuroprotective effects.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

YM348

Cat. No.: HY-100330

YM348 is a potent and orally active **5-HT_{2C} receptor** agonist, which shows a high affinity for cloned human **5-HT_{2C} receptor** (K_i: 0.89 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zacopride hydrochloride

Cat. No.: HY-103137

Zacopride hydrochloride is a highly potent **5-HT_3** receptor antagonist with K_is of 0.38 and 373 nM for **5-HT_3** and **5-HT_4** receptor, respectively. Zacopride hydrochloride is also a moderate I_{K1} channel agonist.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Zatosetron maleate

(LY 277359 maleate)

Cat. No.: HY-U00234

Zatosetron maleate is a potent and selective **5HT3 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zicronapine

(Lu 31-130)

Cat. No.: HY-14827

Zicronapine is an antipsychotic medication with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine has potent antagonistic effects at **dopamine D1/D2**, and **serotonin 5-HT2A receptors**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ziprasidone

(CP-88059)

Cat. No.: HY-14542

Ziprasidone, an antipsychotic agent, is a combined **5-HT (serotonin)** and **dopamine receptor** antagonist. Ziprasidone has high affinity for rat (K_i: 3.4 nM)/human (2.5 nM) 5-HT1A receptors, 5-HT2A (0.42 nM), and dopamine D2 receptors (4.8 nM).



Purity: 98.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ziprasidone amino acid

(Ziprasidone Impurity C; Ziprasidone open ring impurity) Cat. No.: HY-131255

Ziprasidone amino acid (Ziprasidone Impurity C) is an impurity of Ziprasidone. Ziprasidone is a combined **5-HT (serotonin)** and **dopamine receptor** antagonist. Ziprasidone exhibits potent effects of antipsychotic activity .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ziprasidone D8

(CP-88059 D8) Cat. No.: HY-14542S

Ziprasidone D8 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ziprasidone hydrochloride

(CP-88059 hydrochloride) Cat. No.: HY-14542A

Ziprasidone (CP-88059) hydrochloride, an antipsychotic agent, is a combined **5-HT (serotonin)** and **dopamine receptor** antagonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ziprasidone hydrochloride monohydrate

(CP 88059 hydrochloride monohydrate) Cat. No.: HY-17407

Ziprasidone (CP 88059) hydrochloride monohydrate, an antipsychotic agent, is an orally active combined **5-HT (serotonin)** and **dopamine receptor** antagonist.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Zotepine

Cat. No.: HY-103093

Zotepine, an antipsychotic agent, is a potent antagonist of **5-HT$_{2A}$**, **5-HT$_{2C}$**, **Histamine H$_1$**, **α$_1$-adrenergic** and **Dopamine D$_2$ receptors**, with **K$_d$**s of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM and 8 nM, respectively. Zotepine exhibits antidepressive and anxiolytic effects in vivo.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg